<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease - Ni, H - 2022 | Cochrane Library</title> <meta content="Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease - Ni, H - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013506.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease - Ni, H - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013506.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013506.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Han Ni" name="citation_author"/> <meta content="Newcastle University Medicine Malaysia" name="citation_author_institution"/> <meta content="hanni.dr@gmail.com" name="citation_author_email"/> <meta content="Swe Zin Aye" name="citation_author"/> <meta content="Quest International University Perak" name="citation_author_institution"/> <meta content="Cho Naing" name="citation_author"/> <meta content="James Cook University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD013506.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013506.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013506.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013506.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Disease Progression; Dyspnea [drug therapy, etiology]; Ipratropium [therapeutic use]; Magnesium [therapeutic use]; *Magnesium Sulfate [adverse effects]; *Pulmonary Disease, Chronic Obstructive [drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013506.pub2&amp;doi=10.1002/14651858.CD013506.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013506\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013506\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013506.pub2",title:"Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease",firstPublishedDate:"May 26, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013506.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013506.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013506.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013506.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013506.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013506.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013506.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013506.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013506.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013506.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17022 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013506.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-sec-0089"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/appendices#CD013506-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/supinfo/CD013506StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/supinfo/CD013506StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information#CD013506-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Han Ni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information#CD013506-cr-0005">Swe Zin Aye</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information#CD013506-cr-0006">Cho Naing</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information/en#CD013506-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013506.pub2">https://doi.org/10.1002/14651858.CD013506.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013506-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013506-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013506-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013506-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013506-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013506-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013506-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013506-abs-0001" lang="en"> <section id="CD013506-sec-0001"> <h3 class="title" id="CD013506-sec-0001">Background</h3> <p>Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease, often punctuated by recurrent flare‐ups or exacerbations. Magnesium sulfate, having a bronchodilatory effect, may have a potential role as an adjunct treatment in COPD exacerbations. However, comprehensive evidence of its effects is required to facilitate clinical decision‐making. </p> </section> <section id="CD013506-sec-0002"> <h3 class="title" id="CD013506-sec-0002">Objectives</h3> <p>To assess the effects of magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease in adults. </p> </section> <section id="CD013506-sec-0003"> <h3 class="title" id="CD013506-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, the World Health Organization (WHO) trials portal, EU Clinical Trials Register and Iranian Registry of Clinical Trials. We also searched the proceedings of major respiratory conferences and reference lists of included studies up to 2 August 2021. </p> </section> <section id="CD013506-sec-0004"> <h3 class="title" id="CD013506-sec-0004">Selection criteria</h3> <p>We included single‐ or double‐blind parallel‐group randomised controlled trials (RCTs) assessing magnesium sulfate in adults with COPD exacerbations. We excluded cross‐over trials. </p> </section> <section id="CD013506-sec-0005"> <h3 class="title" id="CD013506-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Two review authors independently selected trials for inclusion, extracted data and assessed risk of bias. The primary outcomes were: hospital admissions (from the emergency room); need for non‐invasive ventilation (NIV), assisted ventilation or admission to intensive‐care unit (ICU); and serious adverse events. Secondary outcomes were: length of hospital stay, mortality, adverse events, dyspnoea score, lung function and blood gas measurements. We assessed confidence in the evidence using GRADE methodology. For missing data, we contacted the study investigators. </p> </section> <section id="CD013506-sec-0006"> <h3 class="title" id="CD013506-sec-0006">Main results</h3> <p>We identified 11 RCTs (10 double‐blind and 1 single‐blind) with a total 762 participants. The mean age of participants ranged from 62 to 76 years. Trials were single‐ or two‐centre trials conducted in Iran, New Zealand, Nepal, Turkey, the UK, Tunisia and the USA between 2004 and 2018. We judged studies to be at low or unclear risk of bias for most of the domains. Three studies were at high risk for blinding and other biases.  </p> <p><b>Intravenous magnesium sulfate versus placebo</b> </p> <p>Seven studies (24 to 77 participants) were included. Fewer people may require hospital admission with magnesium infusion compared to placebo (odds ratio (OR) 0.45, 95% CI 0.23 to 0.88; number needed to treat for an additional beneficial outcome (NNTB) = 7; 3 studies, 170 participants; low‐certainty evidence). Intravenous magnesium may result in little to no difference in the requirement for non‐invasive ventilation (OR 0.74, 95% CI 0.31 to 1.75; very low‐certainty evidence). There were no reported cases of endotracheal intubation (2 studies, 107 participants) or serious adverse events (1 study, 77 participants) in either group. Included studies did not report intensive care unit (ICU) admission or deaths. Magnesium infusion may reduce the length of hospital stay by a mean difference (MD) of 2.7 days (95% CI 4.73 days to 0.66 days; 2 studies, 54 participants; low‐certainty evidence) and improve dyspnoea score by a standardised mean difference of ‐1.40 (95% CI ‐1.83 to ‐0.96; 2 studies, 101 participants; low‐certainty evidence). We were uncertain about the effect of magnesium infusion on improving lung function or oxygen saturation. For all adverse events, the Peto OR was 0.14 (95% CI 0.02 to 1.00; 102 participants); however, the event rate was too low to reach a robust conclusion.  </p> <p><b>Nebulised magnesium sulfate versus placebo</b> </p> <p>Three studies (20 to 172 participants) were included. Magnesium inhalation may have little to no impact on hospital admission (OR 0.77, 95% CI 0.21 to 2.82; very low‐certainty evidence) or need for ventilatory support (NIV or mechanical ventilation) (OR 0.33, 95% CI 0.01 to 8.20; very low‐certainty evidence). It may result in fewer ICU admissions compared to placebo (OR 0.39, 95% CI 0.15 to 1.00; very low‐certainty evidence) and improvement in dyspnoea (MD ‐14.37, 95% CI ‐26.00 to ‐2.74; 1 study, 20 participants; very low‐certainty evidence). There were no serious adverse events reported in either group. There was one reported death in the placebo arm in one trial, but the number of participants was too small for a conclusion. There was limited evidence about the effect of magnesium inhalation on length of hospital stay, lung function outcomes or oxygen saturation. Included studies did not report adverse events.  </p> <p><b>Magnesium sulfate versus ipratropium bromide </b> </p> <p>A single study with 124 participants assessed nebulised magnesium sulfate plus intravenous magnesium infusion versus nebulised ipratropium plus intravenous normal saline. There was little to no difference between these groups in terms of hospital admission (OR 1.62, 95% CI 0.78 to 3.37), endotracheal intubation (OR 1.69, 95% CI 0.61 to 4.71) and length of hospital stay (MD 1.10 days, 95% CI ‐0.22 to 2.42), all with very low‐certainty evidence. There were no data available for non‐invasive ventilation, ICU admission and serious adverse events. Adverse events were not reported.  </p> </section> <section id="CD013506-sec-0007"> <h3 class="title" id="CD013506-sec-0007">Authors' conclusions</h3> <p>Intravenous magnesium sulfate may be associated with fewer hospital admissions, reduced length of hospital stay and improved dyspnoea scores compared to placebo. There is no evidence of a difference between magnesium infusion and placebo for NIV, lung function, oxygen saturation or adverse events. We found no evidence for ICU admission, endotracheal intubation, serious adverse events or mortality. </p> <p>For nebulised magnesium sulfate, we are unable to draw conclusions about its effects in COPD exacerbations for most of the outcomes. Studies reported possibly lower ICU admissions and a lesser degree of dyspnoea with magnesium inhalation compared to placebo; however, larger studies are required to yield a more precise estimate for these outcomes. Similarly, we could not identify any robust evidence for magnesium sulfate compared to ipratropium bromide. Future well‐designed multicentre trials with larger samples are required, including subgroups according to severity of exacerbations and COPD phenotypes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013506-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013506-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013506-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013506-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013506-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013506-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013506-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD013506-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013506-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013506-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013506-abs-0002" lang="en"> <h3>Is magnesium sulfate effective for chronic obstructive pulmonary disease (COPD) flare‐ups?</h3> <p><b>Background</b> </p> <p>COPD is a long‐standing disease of the lungs that causes airway narrowing. COPD flare‐ups are episodes of worsening symptoms in people diagnosed with COPD, described as exacerbations in this review. Magnesium sulfate is reported to be able to widen the airways to help breathing. Magnesium sulfate can be given as an infusion into the veins or as an inhalation via a device called a nebuliser. Some studies have shown it to be helpful as an add‐on to usual care in people with COPD flare‐ups. Therefore, we wanted to discover whether using magnesium sulfate was better or worse than other alternatives, such as usual care alone or placebo. Placebo is an infusion or inhalation of normal saline (salt water) through a nebuliser.   </p> <p><b>Study characteristics </b> </p> <p>We included 11 studies involving 762 people with COPD flare‐ups. These studies were funded by local health authorities, researchers or universities where researchers work. Usually, neither the participants nor the people doing the research knew which treatment the participants were getting; although in one study, treatment was known to the people who were doing the research. Studies were done in one or two centres in many countries between 2004 and 2018. The average age of participants ranged from 62 to 76 years. Seven studies tested magnesium infusion, three studies assessed magnesium inhalation, and one study examined both. The evidence in this review is current to 2 August 2021.  </p> <p><b>Key results</b> </p> <p>People who received magnesium infusion may have fewer admissions to hospital from the emergency room. Seven people with COPD flare‐ups would need to be treated with magnesium infusion to prevent one additional person being admitted to hospital. There was little to no difference in terms of breathing support without intubation (putting a tube into the windpipe to help a person to breathe). None of the participants required breathing support with intubation. Included studies did not report ICU admission or deaths. Only one trial reported on serious adverse events, but no‐one in the study experienced any. Magnesium infusion may shorten the duration of hospital stay and reduce breathlessness. However, we were not clear about its effect on lung function, oxygen concentration in blood or adverse events.  </p> <p>Magnesium inhalation (nebuliser) had little or no effect on hospital admission or the need for breathing support (with or without intubation) compared to placebo. Nebulised magnesium may reduce ICU admission and improve breathlessness. However, we are not confident of these findings due to small number of participants and study limitations. There is no evidence of a difference for duration of hospital stay, lung function or oxygen saturation in blood. Serious adverse events were not reported. There is no available data for adverse events. One trial reported one death in the placebo group, but we are not confident to draw any conclusion as the trial had very few participants. </p> <p>Only one study compared magnesium sulfate inhalation and infusion versus inhaled ipratropium bromide and placebo infusion. We could not identify any differences between the effects of these treatments. </p> <p><b>Limitations of the evidence </b> </p> <p>Magnesium infusion may reduce hospital admissions, shorten length of hospital stay and improve breathlessness compared to placebo. We are very uncertain about its effect on the need for breathing support, lung function or blood oxygen concentration because the studies were small. We do not have enough information to assess any effects on serious adverse events or deaths. The effects of magnesium inhalation compared to placebo or magnesium sulfate versus ipratropium bromide are unclear.  </p> <p>Magnesium sulfate infusion may be useful as an add‐on treatment for COPD flare‐ups. However, we cannot draw conclusions about whether magnesium sulfate inhalation is helpful for use in people with COPD flare‐ups.  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013506-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013506-sec-0098"></div> <h3 class="title" id="CD013506-sec-0099">Implications for practice</h3> <section id="CD013506-sec-0099"> <p>We have limited confidence to conclude a possible beneficial effect of intravenous magnesium sulfate infusion in reducing the number of people admitted to hospital from the emergency room, shortening length of hospital stay and improving dyspnoea. We could not identify evidence for intensive care unit (ICU) admission or endotracheal intubation. We had very little confidence in the effect of magnesium infusion on the need for non‐invasive ventilation (NIV), or for improving lung function and oxygen saturation. Since the data on adverse events, serious adverse events and mortality were limited, further safety data are required before using intravenous magnesium infusion as a routine addition to standard care in people with chronic obstructive pulmonary disease (COPD) exacerbations. </p> <p>Current evidence for inhaled magnesium sulfate is very uncertain, and could not demonstrate that it is beneficial in reducing hospital admissions, the need for ventilatory support, length of hospital stay or all‐cause mortality, or in improving lung function and oxygen saturation. Fewer ICU admissions were noted with nebulised magnesium, and a small trial favoured inhaled magnesium over placebo in improving dyspnoea, though we graded both these outcomes as very uncertain evidence. </p> <p>Similarly, evidence from a single trial was very uncertain and could not demonstrate a clear benefit of magnesium over ipratropium bromide on the need for hospital admission or endotracheal intubation, length of hospital stay or all‐cause mortality. </p> <p>Overall, the evidence in this review should be interpreted with caution as larger studies are required to demonstrate the effects of magnesium sulfate in COPD exacerbations. </p> </section> <h3 class="title" id="CD013506-sec-0100">Implications for research</h3> <section id="CD013506-sec-0100"> <p>Further research is indicated, including multicentre trials in larger populations with COPD exacerbations (better‐powered trials) using robust methods, which should be reported transparently. Trialists should define and categorise participants according to severity of COPD exacerbations and, if possible, provide disaggregated data for different groups. It is also recommended to include COPD phenotypes of participants to delineate the possible impact of asthma/COPD overlap on the evidence. Further trials assessing the effects of magnesium sulfate with participant‐related outcomes (e.g. ICU admission, need for NIV or mechanical ventilation, length of hospital stay and dyspnoea score) as primary endpoints rather than lung function improvement would be more appropriate for applicability to clinical practice in people with COPD exacerbations. Follow‐up data would be beneficial, especially to identify any impact of magnesium sulfate on recurrent exacerbations and readmissions. Since currently available evidence did not identify any study on cost‐effectiveness, future research on this outcome is also required. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013506-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013506-sec-0008"></div> <div class="table" id="CD013506-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravenous magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intravenous magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute exacerbations of chronic obstructive pulmonary disease<br/><b>Setting:</b> emergency department<br/><b>Intervention:</b> intravenous magnesium sulfate + standard care<br/><b>Comparison:</b> placebo + standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravenous magnesium sulfate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people with hospital admissions (from the emergency room)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>593 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>396 per 1000<br/>(251 to 562) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.45<br/>(0.23 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people requiring non‐invasive ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>314 per 1000<br/>(161 to 519) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/>(0.31 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no people who need endotracheal intubation in either magnesium or placebo groups. No trial assessed ICU admission. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people with serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no reported serious adverse events for magnesium and placebo groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay ranged from 5.47 to 7.33 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.7 days shorter<br/>(4.73 shorter to 0.66 shorter) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in oxygen saturation (SpO<sub>2</sub>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SpO<sub>2</sub> was 8.42% </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.32% higher<br/>(1.53 lower to 2.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in dyspnoea score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dyspnoea score ranged from 1.08 to 2.05</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 1.4 lower<br/>(1.83 lower to 0.96 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSS score and Borg dyspnoea score were used. The lower the score, the lesser the severity of dyspnoea. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function: FEV<sub>1</sub> change from baseline at 60 min </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> at 60 min was 0.043 L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.0 L<br/>(0.04 lower to 0.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><br/>CI: confidence interval; DSS: dyspnoea severity score; FEV<sub>1</sub>: forced expiratory volume in 1 second; RCT: randomised controlled trial; OR: odds ratio; MD: mean difference; SpO<sub>2</sub>: peripheral oxygen saturation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations (risk of selection, performance, detection and reporting bias)<br/><sup>b</sup>Downgraded one level for serious imprecision (few events or wide confidence interval)<br/><sup>c</sup>Downgraded two levels for very serious imprecision (few events and CI includes both appreciable benefit and harm) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013506-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nebulised magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Nebulised magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute exacerbations of chronic obstructive pulmonary disease<br/><b>Setting:</b> emergency department<br/><b>Intervention:</b> nebulised magnesium sulfate + standard care<br/><b>Comparison:</b> placebo + standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with nebulised magnesium sulfate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people with hospital admissions (from the emergency room)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>918 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>896 per 1000<br/>(702 to 969) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.77<br/>(0.21 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people requiring ICU admission</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/>(18 to 109) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.39<br/>(0.15 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people requiring ventilatory support (NIV or assisted ventilation)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(0 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.33<br/>(0.01 to 8.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of people with serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trial assessed this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay was 10.2 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.8 lower<br/>(4.63 lower to 3.03 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in oxygen saturation (SaO<sub>2</sub>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SaO<sub>2</sub> was 4% </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.1% lower<br/>(4.6 lower to 2.4 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in dyspnoea score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dyspnoea score was 9.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 14.37 lower<br/>(26 lower to 2.74 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS dyspnoea score was used. The higher the score, the greater the severity of dyspnoea.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function: FEV<sub>1</sub> at 60 min </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> at 60 min was 0.81 L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.05 L lower<br/>(0.17 lower to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in 1 second; ICU: intensive care unit ; RCT: randomised controlled trial; SaO<sub>2</sub>: arterial oxygen saturation; OR: odds ratio; MD: mean difference; VAS: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations (risk of selection and reporting bias)<br/><sup>b</sup>Downgraded two levels for study limitations (risk of selection, reporting bias and very small participant numbers)<br/><sup>c</sup>Downgraded two levels for very serious imprecision (few events and CI includes both appreciable benefit and harm)<br/><sup>d</sup>Downgraded one level for serious imprecision (few events or CI includes non‐appreciable benefit and potential harm)<br/><sup>e</sup>Downgraded two levels for study limitations (single blinded study with high risk of performance bias) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013506-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Magnesium sulfate compared to standard care (ipratropium bromide) for acute exacerbations of chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Magnesium sulfate compared to (standard care) ipratropium bromide for acute exacerbations of chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute exacerbations of chronic obstructive pulmonary disease<br/><b>Setting:</b> emergency department<br/><b>Intervention:</b> magnesium sulfate<br/><b>Comparison:</b> ipratropium bromide </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ipratropium bromide</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with magnesium sulfate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people with hospital admissions (from the emergency room)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>323 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000<br/>(271 to 616) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.62<br/>(0.78 to 3.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people requiring endotracheal intubation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000<br/>(72 to 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.69<br/>(0.61 to 4.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU admission or non‐invasive ventilation not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of people with serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay was 6.6 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.1 higher<br/>(0.22 lower to 2.42 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in oxygen saturation (SaO<sub>2</sub>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in dyspnoea score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lung function: FEV<sub>1</sub> at 60 min </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in 1 second; ICU: intensive care unit ; RCT: randomised controlled trial; SaO<sub>2</sub>: arterial oxygen saturation; OR: odds ratio; MD: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (few events and CI includes both appreciable benefit and harm)<br/><sup>b</sup>Downgraded one level for study limitations (risk of detection and other bias) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013506-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013506-sec-0009"></div> <section id="CD013506-sec-0010"> <h3 class="title" id="CD013506-sec-0010">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases characterised by airflow obstruction that interferes with normal breathing (<a href="./references#CD013506-bbs2-0033" title="American Lung Association.Trends in COPD (chronic bronchitis and emphysema): morbidity and mortality; 2013. www.lung.org/getmedia/4f74781e-481f-4f10-9255-8dfc9dc56974/copd-trend-report.pdf.pdf.">American Lung Association 2013</a>). Clinical diagnosis of COPD is considered in people who experience breathlessness, chronic cough or sputum production, with a history of exposure to known risk factors (<a href="./references#CD013506-bbs2-0108" title="World Health Organization.Chronic obstructive pulmonary disease (COPD) Fact sheets; 21 June 2021. www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (accessed prior to 4 May 2022).">WHO 2021</a>). Smoking and ambient particulate matter are the main risk factors for COPD (<a href="./references#CD013506-bbs2-0056" title="Chronic Respiratory Disease Collaborators.Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma,1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respiratory Medicine2017;5:691-706.">GBD 2017</a>). Confirmation of COPD requires spirometry to demonstrate persistent airflow limitation according to the criterion of a postbronchodilator forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC) ratio of less than 0.7 (<a href="./references#CD013506-bbs2-0059" title="2021 Global Strategy for Prevention, Diagnosis and Management of COPD. goldcopd.org/2021-gold-reports/ (accessed 30 September 2021).">GOLD 2021</a>). </p> <p>There were an estimated 3.17 million COPD‐related deaths, accounting for 5% of total deaths globally, in 2015 (<a href="./references#CD013506-bbs2-0108" title="World Health Organization.Chronic obstructive pulmonary disease (COPD) Fact sheets; 21 June 2021. www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (accessed prior to 4 May 2022).">WHO 2021</a>). According to the Global Burden of Disease (GBD) study, 251 million people had COPD worldwide in 2016, and it caused 2.6% of disability‐adjusted life years in 2015 alone (<a href="./references#CD013506-bbs2-0056" title="Chronic Respiratory Disease Collaborators.Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma,1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respiratory Medicine2017;5:691-706.">GBD 2017</a>). In 2016, chronic respiratory diseases contributed to 8.96% of worldwide non‐communicable disease deaths, of which 2.93 million deaths were due to COPD (<a href="./references#CD013506-bbs2-0088" title="NaghaviM , AbajobirAA , AbbafatiC , AbbasKM , Abd-AllahF , AberaSF , et al.Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2017;390:1151–210.">Ngahavi 2017</a>). In the 1990s, COPD was the sixth leading cause of death; it has become the fourth leading cause since 2000 and is the third leading cause of death worldwide, causing 3.23 million deaths in 2019 (<a href="./references#CD013506-bbs2-0059" title="2021 Global Strategy for Prevention, Diagnosis and Management of COPD. goldcopd.org/2021-gold-reports/ (accessed 30 September 2021).">GOLD 2021</a>; <a href="./references#CD013506-bbs2-0082" title="Lopez-CamposJL , TanW , SorianoJB .Global burden of COPD. Respirology2016;21(1):14-23. [PMID: 26494423]">Lopez‐Campos 2016</a>; <a href="./references#CD013506-bbs2-0107" title="WHO Global Health Estimates: The top 10 causes of death; 2020. www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.">WHO 2020</a>). The principal causes of death in people with mild to moderate COPD are lung cancer (26.5%) and cardiovascular disease (21.6%), while acute respiratory failure (25.8%) is the main cause of death in people with very severe COPD, based on the analysis of 2826 deaths in 13 Spanish centres (<a href="./references#CD013506-bbs2-0102" title="Soto-CamposJG , PlazaV , SorianoJB , Cabrera-LopezC , Almonacid-SanchezC , Vazquez-OlivaR , et al.Causes of death in asthma, COPD and non-respiratory hospitalised patients: a multicentric study. BMC Pulmonary Medicine2013;13:73. [PMID: 24321217]">Soto‐Campos 2013</a>). Morbidity due to COPD is also high worldwide, with 29.4 million years lost due to disability in 2015 (<a href="./references#CD013506-bbs2-0082" title="Lopez-CamposJL , TanW , SorianoJB .Global burden of COPD. Respirology2016;21(1):14-23. [PMID: 26494423]">Lopez‐Campos 2016</a>). </p> <p>The chronic and progressive course of COPD is often punctuated by episodes of exacerbations. Exacerbations are defined as "an acute worsening of respiratory symptoms that result in additional therapy" (<a href="./references#CD013506-bbs2-0059" title="2021 Global Strategy for Prevention, Diagnosis and Management of COPD. goldcopd.org/2021-gold-reports/ (accessed 30 September 2021).">GOLD 2021</a>; <a href="./references#CD013506-bbs2-0090" title="O'DonnellDE , ParkerCM .COPD exacerbations: pathophysiology. Thorax2006;61(4):354-61. [PMID: 16565268]">O'Donnell 2006</a>; <a href="./references#CD013506-bbs2-0106" title="WedzichaJA , MiravitllesM , HurstJR , CalverleyPM , AlbertRK , AnzuetoA , et al.Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal2017;49(3):1600791. [PMID: 28298398]">Wedzicha 2017</a>). COPD exacerbations are more frequent in the winter months for people living in temperate climates (<a href="./references#CD013506-bbs2-0071" title="JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al.Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38-45. [PMID: 21737561]">Jenkins 2012</a>), and are mainly triggered by respiratory infections (<a href="./references#CD013506-bbs2-0105" title="WedzichaJA , SeemungalTA .COPD exacerbations: defining their cause and prevention. Lancet2007;370(9589):786-96. [PMID: 17765528]">Wedzicha 2007</a>). Other non‐infective causes, such as air pollution and pulmonary embolus, can also trigger the exacerbations (<a href="./references#CD013506-bbs2-0042" title="CelliBR , BarnesPJ .Exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2007;29:1224-38. [DOI: 10.1183/09031936.00109906]">Celli 2007</a>). People experience worsening symptoms, including breathlessness or cough with increased sputum volume or purulence, and require increased use of maintenance medications. Mild exacerbations can be treated with short‐acting bronchodilators only, whereas more severe exacerbations require the addition of a course of systemic steroids or antibiotics, hospitalisation or an emergency room visit (<a href="./references#CD013506-bbs2-0059" title="2021 Global Strategy for Prevention, Diagnosis and Management of COPD. goldcopd.org/2021-gold-reports/ (accessed 30 September 2021).">GOLD 2021</a>). These exacerbations, especially when frequent, can compromise quality of life (<a href="./references#CD013506-bbs2-0045" title="Connors AF Jr, DawsonNV , ThomasC , Harrell FE Jr, DesbiensN , FulkersonWJ , et al.Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). American Journal of Respiratory and Critical Care Medicine1996;154(4 Pt 1):959-67. [PMID: 8887592]">Connors 1996</a>; <a href="./references#CD013506-bbs2-0048" title="DavidA , CorlateanuA .Influence of COPD exacerbations on health related quality of life. European Respiratory Journal2012;40:P4821.">David 2012</a>; <a href="./references#CD013506-bbs2-0084" title="MiravitllesM , FerrerM , PontA , ZalacainR , Alvarez-SalaJL , MasaF , et al.Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax2004;59(5):387-95. [PMID: 15115864]">Miravitlles 2004</a>; <a href="./references#CD013506-bbs2-0098" title="SeemungalTA , DonaldsonGC , PaulEA , BestallJC , JeffriesDJ , WedzichaJA .Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998;157(5 Pt 1):1418-22. [PMID: 9603117]">Seemungal 1998</a>; <a href="./references#CD013506-bbs2-0103" title="SpencerS , CalverleyPM , Sherwood BurgeP , JonesPW .Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122-8. [PMID: 11208636]">Spencer 2001</a>), accelerate lung function decline (<a href="./references#CD013506-bbs2-0034" title="AnzuetoA , LeimerI , KestenS .Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. International Journal of Chronic Obstructive Pulmonary Disease2009;4:245-51. [PMID: 19657398]">Anzueto 2009</a>; <a href="./references#CD013506-bbs2-0043" title="CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al.Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332-8. [PMID: 18511702]">Celli 2008</a>; <a href="./references#CD013506-bbs2-0050" title="DonaldsonGC , SeemungalTA , BhowmikA , WedzichaJA .Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax2002;57(10):847-52. [PMID: 12324669]">Donaldson 2002</a>), reduce physical capacity (<a href="./references#CD013506-bbs2-0051" title="DonaldsonGC , WilkinsonTM , HurstJR , PereraWR , WedzichaJA .Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2005;171(5):446-52. [PMID: 15579723]">Donaldson 2005</a>; <a href="./references#CD013506-bbs2-0091" title="PittaF , TroostersT , ProbstVS , SpruitMA , DecramerM , GosselinkR .Physical activity and hospitalisation for exacerbation of COPD. Chest2006;129(3):536-44. [PMID: 16537849]">Pitta 2006</a>), result in hospital admissions (<a href="./references#CD013506-bbs2-0086" title="MullerovaH , MaselliDJ , LocantoreN , VestboJ , HurstJR , WedzichaJA , et al.Hospitalised exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest2015;147(4):999-1007. [PMID: 25356881]">Mullerova 2015</a>), and increase mortality (<a href="./references#CD013506-bbs2-0031" title="AlmagroP , CalboE , Ochoa de EchaguenA , BarreiroB , QuintanaS , HerediaJL , et al.Mortality after hospitalisation for COPD. Chest2002;121(5):1441-8. [PMID: 12006426]">Almagro 2002</a>; <a href="./references#CD013506-bbs2-0064" title="GroenewegenKH , ScholsAM , WoutersEF .Mortality and mortality-related factors after hospitalisation for acute exacerbation of COPD. Chest2003;124(2):459-67. [PMID: 12907529]">Groenewegen 2003</a>; <a href="./references#CD013506-bbs2-0100" title="Soler-CatalunaJJ , Martinez-GarciaMA , Roman SanchezP , SalcedoE , NavarroM , OchandoR .Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax2005;60(11):925-31. [PMID: 16055622]">Soler‐Cataluna 2005</a>). In addition, severe COPD exacerbations that require hospital admission exert a direct and independent effect on survival, with a reported mortality rate of 50% within five years, similar to an oncologic mortality rate (<a href="./references#CD013506-bbs2-0055" title="Garcia-AymerichJ , Serra PonsI , ManninoDM , MaasAK , MillerDP , DavisKJ .Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax2011;66(7):585-90. [PMID: 21515553]">Garcia‐Aymerich 2011</a>; <a href="./references#CD013506-bbs2-0087" title="NanniniLJ .Hospitalization due to COPD exacerbation. Chest2012;142(6):1697. [PMID: 23208363]">Nannini 2012</a>). </p> <p>Acute COPD exacerbations are reported to be more frequent in people with severe disease, with an annual exacerbation frequency of 3.43, compared with 2.68 for those with moderate disease (<a href="./references#CD013506-bbs2-0035" title="AnzuetoA .Impact of exacerbations on COPD. European Respiratory Review2010;19(116):113-8. [PMID: 20956179]">Anzueto 2010</a>). Similarly, in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End‐points) study, exacerbation rates in the first year of follow‐up were 0.85, 1.34 and 2.00 per person for people with GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 2, 3 and 4, respectively, while 22%, 33% and 47% were reported to have two or more exacerbations over the same period (<a href="./references#CD013506-bbs2-0069" title="HurstJR , VestboJ , AnzuetoA , LocantoreN , MullerovaH , Tal-SingerR , et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine2010;363(12):1128-38. [DOI: 10.1056/NEJMoa0909883]">Hurst 2010</a>). However, most of the COPD exacerbation data have been estimated in populations with moderate to severe COPD requiring hospital care, thus leading to the possibility of a higher number of less severe forms being under‐diagnosed (<a href="./references#CD013506-bbs2-0039" title="BorrellE , RodriguezM , ToranP , MunozL , PeraG , MontellaN , et al.Incidence and risk factors of exacerbations among COPD patients in primary health care: APMPOC study. BMC Public Health2009;9:8.">Borrell 2009</a>). </p> </section> <section id="CD013506-sec-0011"> <h3 class="title" id="CD013506-sec-0011">Description of the intervention</h3> <p>Magnesium is the second most common intracellular cation in the body, found principally in bone (53%), muscle (27%) and soft tissues (19%); less than 1% of total body magnesium is present in the blood (<a href="./references#CD013506-bbs2-0052" title="ElinRJ .Magnesium metabolism in health and disease. Disease-a-month1988;34(4):161-218. [PMID: 3282851]">Elin 1988</a>; <a href="./references#CD013506-bbs2-0054" title="FawcettWJ , HaxbyEJ , MaleDA .Magnesium: physiology and pharmacology. British Journal of Anaesthesia1999;83(2):302-20. [PMID: 10618948]">Fawcett 1999</a>). It is involved in many biological actions, such as energy production, glycolysis (breakdown of glucose), synthesis of nucleic acids and proteins, transmembrane ion flux, regulation of adenylate cyclase, muscle contraction and neuronal activity (<a href="./references#CD013506-bbs2-0047" title="CostelloR , WallaceTC , RosanoffA .Magnesium. Advances in Nutrition2016;7(1):199-201. [PMID: 26773023]">Costello 2016</a>; <a href="./references#CD013506-bbs2-0063" title="GroberU , SchmidtJ , KistersK .Magnesium in prevention and therapy. Nutrients2015;7(9):8199-226. [PMID: 26404370]">Grober 2015</a>; <a href="./references#CD013506-bbs2-0095" title="RomaniAM .Magnesium in health and disease. Metal Ions in Life Sciences2013;13:49-79. [PMID: 24470089]">Romani 2013</a>). It acts as a physiological calcium channel antagonist, stimulates prostacyclin and nitric oxide production, and diminishes vascular reactivity to a variety of pressor agents (drugs to increase blood pressure) (<a href="./references#CD013506-bbs2-0054" title="FawcettWJ , HaxbyEJ , MaleDA .Magnesium: physiology and pharmacology. British Journal of Anaesthesia1999;83(2):302-20. [PMID: 10618948]">Fawcett 1999</a>; <a href="./references#CD013506-bbs2-0077" title="LairesMJ , MonteiroCP , BichoM .Role of cellular magnesium in health and human disease. Frontiers in Bioscience2004;9:262-76. [PMID: 14766364]">Laires 2004</a>). Magnesium prevents calcium ion movement into vascular and bronchial smooth muscle cells via voltage‐dependent calcium channels, so it is believed to play a major role in vasodilatation and bronchodilatation (<a href="./references#CD013506-bbs2-0061" title="GourgoulianisKI , ChatziparasidisG , ChatziefthimiouA , MolyvdasPA .Magnesium as a relaxing factor of airway smooth muscles. Journal of Aerosol Medicine2001;14(3):301-7. [PMID: 11693841]">Gourgoulianis 2001</a>; <a href="./references#CD013506-bbs2-0073" title="KewKM , KirtchukL , MichellCI .Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD010909. [DOI: 10.1002/14651858.CD010909.pub2]">Kew 2014</a>; <a href="./references#CD013506-bbs2-0104" title="SpiveyWH , SkobeloffEM , LevinRM .Effect of magnesium chloride on rabbit bronchial smooth muscle. Annals of Emergency Medicine1990;19(10):1107-12. [PMID: 1977337]">Spivey 1990</a>). Magnesium also inhibits the release of acetylcholine from cholinergic nerve endings and histamine from mast cells, leading to possible anticholinergic and antihistamine effects (<a href="./references#CD013506-bbs2-0049" title="Del-CastilloJ , EngbaekL .The nature of the neuromuscular block produced by magnesium. Journal of Physiology1954;124(2):370-84. [PMID: 13175138]">Del‐Castillo 1954</a>). Furthermore, some evidence suggests that magnesium may reduce the neutrophilic burst of inflammatory response with a possible beneficial anti‐inflammatory effect (<a href="./references#CD013506-bbs2-0041" title="CairnsCB , KraftM .Magnesium attenuates the neutrophil respiratory burst in adult asthmatic patients. Academic Emergency Medicine1996;3(12):1093-7. [PMID: 8959161]">Cairns 1996</a>). </p> <p>Recent clinical guidelines advise that a single dose of intravenous magnesium sulfate can be considered for adults with severe life‐threatening asthma exacerbations, adults and children who fail to respond to initial treatment with persistent hypoxaemia, and children who fail to achieve 60% of predicted FEV<sub>1</sub> value after one hour of care. The recommended dosage of intravenous magnesium sulfate for adults is 1.2 g to 2 g, delivered by infusion over 20 minutes (<a href="./references#CD013506-bbs2-0040" title="Scottish Intercollegiate Guidelines Network, British Thoracic Society.British guideline on the management of asthma: a national clinical guideline: revised edition published July 2019. www.sign.ac.uk/sign-158-british-guideline-on-the-management-of-asthma.html.">BTS/SIGN 2019</a>; <a href="./references#CD013506-bbs2-0058" title="Global Initiative for Asthma: Global strategy for asthma management and prevention (2018 update). ginasthma.org/gina-ebooks (accessed 30 March 2019).">GINA 2018</a>). However, routine use of magnesium sulfate in acute exacerbations of asthma is not recommended (<a href="./references#CD013506-bbs2-0058" title="Global Initiative for Asthma: Global strategy for asthma management and prevention (2018 update). ginasthma.org/gina-ebooks (accessed 30 March 2019).">GINA 2018</a>). Similarly, nebulised magnesium sulfate is not routinely recommended for adults with acute asthma or children with mild to moderate asthma attacks, although 150 mg of nebulised magnesium sulfate can be considered as an adjunct to nebulised salbutamol and ipratropium in the first hour for children with severe asthma exacerbations (<a href="./references#CD013506-bbs2-0040" title="Scottish Intercollegiate Guidelines Network, British Thoracic Society.British guideline on the management of asthma: a national clinical guideline: revised edition published July 2019. www.sign.ac.uk/sign-158-british-guideline-on-the-management-of-asthma.html.">BTS/SIGN 2019</a>). </p> </section> <section id="CD013506-sec-0012"> <h3 class="title" id="CD013506-sec-0012">How the intervention might work</h3> <p>The characteristic response in COPD exacerbations is increased airway inflammation, hyperinflation and gas trapping, with reduced expiratory flow accounting for increased breathlessness. Treatment of acute exacerbation of COPD aims to minimise the negative impact of the episode and prevent subsequent events. The current guidelines recommend the use of short‐acting beta<sub>2</sub>‐agonists (SABA), muscarinic antagonists, systemic corticosteroids, antibiotics and non‐invasive ventilation for COPD exacerbations (<a href="./references#CD013506-bbs2-0059" title="2021 Global Strategy for Prevention, Diagnosis and Management of COPD. goldcopd.org/2021-gold-reports/ (accessed 30 September 2021).">GOLD 2021</a>). </p> <p>Magnesium sulfate may have potential benefits as an adjunct therapy in acute exacerbations of COPD. This is because low serum magnesium levels are reported to be associated with an increased risk of exacerbation in people with COPD, according to a retrospective study (<a href="./references#CD013506-bbs2-0037" title="AzizHS , BlamounAI , ShubairMK , IsmailMM , DeBariVA , KhanMA .Serum magnesium levels and acute exacerbation of chronic obstructive pulmonary disease: a retrospective study. Annals of Clinical and Laboratory Science2005;35(4):423-7. [PMID: 16254259]">Aziz 2005</a>), and a small prospective study (<a href="./references#CD013506-bbs2-0065" title="GumusA , HazirogluM , GunesY .Association of serum magnesium levels with frequency of acute exacerbations in chronic obstructive pulmonary disease: a prospective study. Pulmonary Medicine2014;2014:329476. [DOI: 10.1155/2014/329476] [PMID: 25485151]">Gumus 2014</a>). Moreover, studies have reported that hypomagnesaemia (low serum magnesium level) is an independent predictor of frequent readmission for acute exacerbations of COPD (<a href="./references#CD013506-bbs2-0038" title="BhattSP , KhandelwalP , NandaS , StoltzfusJC , FioravantiGT .Serum magnesium is an independent predictor of frequent readmissions due to acute exacerbation of chronic obstructive pulmonary disease. Respiratory Medicine2008;102(7):999-1003. [PMID: 18396393]">Bhatt 2008</a>), or exacerbation frequency in people with COPD (<a href="./references#CD013506-bbs2-0065" title="GumusA , HazirogluM , GunesY .Association of serum magnesium levels with frequency of acute exacerbations in chronic obstructive pulmonary disease: a prospective study. Pulmonary Medicine2014;2014:329476. [DOI: 10.1155/2014/329476] [PMID: 25485151]">Gumus 2014</a>). </p> <p>Intravenous magnesium sulfate, in addition to bronchodilators, reduces hospital admissions and improves lung function when the response to bronchodilators during acute asthma exacerbations is inadequate (<a href="./references#CD013506-bbs2-0073" title="KewKM , KirtchukL , MichellCI .Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD010909. [DOI: 10.1002/14651858.CD010909.pub2]">Kew 2014</a>; <a href="./references#CD013506-bbs2-0096" title="RoweBH , BretzlaffJ , BourdonC , BotaG , BlitzS , Camargo JrCA .Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2000, Issue 1. Art. No: CD001490. [DOI: 10.1002/14651858.CD001490]">Rowe 2000</a>). However, evidence for the use of inhaled magnesium sulfate during acute exacerbations of asthma, either alone or in addition to bronchodilators, does not demonstrate clinically important benefits, and further trials are needed to establish its usefulness (<a href="./references#CD013506-bbs2-0074" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al.Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). </p> <p>Over the past few years, there has been a marked interest in a subset of people with airways disease who have features of both asthma and COPD, known as asthma‐COPD overlap (ACO) (<a href="./references#CD013506-bbs2-0046" title="CosioBG , DacalD , Perez de LlanoL .Asthma-COPD overlap: identification and optimal treatment. Therapeutic Advances in Respiratory Disease2018;12:1753466618805662. [DOI: 10.1177/1753466618805662] [PMID: 30336736]">Cosio 2018</a>). People with asthma who smoke are reported to have more symptoms than people with asthma who do not smoke (<a href="./references#CD013506-bbs2-0080" title="LeungJM , SinDD .Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. BMJ2017;358:j3772. [PMID: 28947632]">Leung 2017</a>). In the absence of a standard definition for ACO diagnosis, the prevalence estimates vary from 3.2% in the USA (<a href="./references#CD013506-bbs2-0076" title="KumbhareS , PleasantsR , OharJA , StrangeC .Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. Annals of the American Thoracic Society2016;13(6):803-10. [PMID: 26974689]">Kumbhare 2016</a>), to 11.1% in Italy (<a href="./references#CD013506-bbs2-0101" title="SorinoC , PedoneC , ScichiloneN .Fifteen-year mortality of patients with asthma-COPD overlap syndrome. European Journal of Internal Medicine2016;34:72-7. [PMID: 27357368]">Sorino 2016</a>). The prevalence of ACO ranges from 6% to 55% in cohorts of people with COPD, and from 10% to 31% in cohorts of people with asthma (<a href="./references#CD013506-bbs2-0080" title="LeungJM , SinDD .Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. BMJ2017;358:j3772. [PMID: 28947632]">Leung 2017</a>). People with ACO have more severe and frequent exacerbations, and have thicker airway walls than people with COPD alone (<a href="./references#CD013506-bbs2-0066" title="HardinM , ChoM , McDonaldML , BeatyT , RamsdellJ , BhattS , et al.The clinical and genetic features of COPD-asthma overlap syndrome. European Respiratory Journal2014;44(2):341-50. [PMID: 24876173]">Hardin 2014</a>), leading to more hospitalisations and emergency department visits (<a href="./references#CD013506-bbs2-0076" title="KumbhareS , PleasantsR , OharJA , StrangeC .Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. Annals of the American Thoracic Society2016;13(6):803-10. [PMID: 26974689]">Kumbhare 2016</a>). Furthermore, they have a significantly lower quality of life (<a href="./references#CD013506-bbs2-0072" title="KauppiP , KupiainenH , LindqvistA , TammilehtoL , KilpelainenM , KinnulaVL , et al.Overlap syndrome of asthma and COPD predicts low quality of life. Journal of Asthma2011;48(3):279-85. [PMID: 21323613]">Kauppi 2011</a>), a more rapid decline in lung function (<a href="./references#CD013506-bbs2-0078" title="LangeP , ColakY , IngebrigtsenTS , VestboJ , MarottJL .Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respiratory Medicine2016;4(6):454-62. [PMID: 27061878]">Lange 2016</a>), higher disease burden (including respiratory symptoms and activity limitation) (<a href="./references#CD013506-bbs2-0068" title="HinesKL , Peebles RS Jr.Management of the asthma-COPD overlap syndrome (ACOS): a review of the evidence. Current Allergy and Asthma Reports2017;17(3):15. [PMID: 28283854]">Hines 2017</a>), and a higher mortality rate compared to people with asthma or COPD alone (<a href="./references#CD013506-bbs2-0057" title="GibsonPG , SimpsonJL .The overlap syndrome of asthma and COPD: what are its features and how important is it?Thorax2009;64(8):728-35. [PMID: 19638566]">Gibson 2009</a>; <a href="./references#CD013506-bbs2-0101" title="SorinoC , PedoneC , ScichiloneN .Fifteen-year mortality of patients with asthma-COPD overlap syndrome. European Journal of Internal Medicine2016;34:72-7. [PMID: 27357368]">Sorino 2016</a>). As some people with COPD may also have asthmatic features, it is reasonable to assume there may be some benefits of magnesium sulfate for acute exacerbations of COPD, as well as for acute asthma. Moreover, bronchodilatation (<a href="./references#CD013506-bbs2-0104" title="SpiveyWH , SkobeloffEM , LevinRM .Effect of magnesium chloride on rabbit bronchial smooth muscle. Annals of Emergency Medicine1990;19(10):1107-12. [PMID: 1977337]">Spivey 1990</a>), anticholinergic (<a href="./references#CD013506-bbs2-0049" title="Del-CastilloJ , EngbaekL .The nature of the neuromuscular block produced by magnesium. Journal of Physiology1954;124(2):370-84. [PMID: 13175138]">Del‐Castillo 1954</a>) and anti‐inflammatory properties of magnesium (<a href="./references#CD013506-bbs2-0041" title="CairnsCB , KraftM .Magnesium attenuates the neutrophil respiratory burst in adult asthmatic patients. Academic Emergency Medicine1996;3(12):1093-7. [PMID: 8959161]">Cairns 1996</a>) could lead to potential therapeutic effects for acute exacerbations of COPD. </p> </section> <section id="CD013506-sec-0013"> <h3 class="title" id="CD013506-sec-0013">Why it is important to do this review</h3> <p>Exacerbations play a major role in the morbidity and mortality of people with COPD, resulting in a significant health burden. Therefore, a potentially effective add‐on treatment would be useful for people with COPD and healthcare providers. The potential clinical benefits of intravenous or nebulised magnesium sulfate for acute exacerbations of COPD have been studied; however, published studies have found conflicting and inconclusive results for its effectiveness. A non‐Cochrane systematic review on magnesium sulfate reported that it appeared to potentiate the bronchodilatory effect of inhaled beta<sub>2</sub>‐agonists, but did not find differences in dyspnoea scores, hospital admission rates, or emergency department readmission rates, compared to placebo (<a href="./references#CD013506-bbs2-0099" title="ShivanthanMC , RajapakseS .Magnesium for acute exacerbation of chronic obstructive pulmonary disease: a systematic review of randomised trials. Annals of Thoracic Medicine2014;9(2):77-80.">Shivanthan 2014</a>). Another recent review demonstrated a reduction in hospital admissions in people with COPD exacerbations receiving magnesium sulfate infusion (<a href="./references#CD013506-bbs2-0070" title="JahangirA , ZiaZ , NiaziMR , SahraS , JahangirA , SharifMA , et al.Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: a systematic review and meta-analysis. Advances in Respiratory Medicine 2022 Jan 31 [Epub ahead of print]. [DOI: 10.5603/ARM.a2022.0012] [PMID: 35099052]">Jahangir 2022</a>). Currently, standard guidelines do not recommend magnesium sulfate as a treatment for acute exacerbation of COPD, but it is nonetheless used by some clinicians in practice. Therefore, we would like to establish evidence regarding its usage as an adjunct treatment for acute exacerbations of COPD in people not responding to conventional measures, based on current available data from randomised controlled trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013506-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013506-sec-0014"></div> <p>To assess the effects of magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013506-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013506-sec-0015"></div> <section id="CD013506-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013506-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with a parallel‐group design, regardless of the language in which they were published. We included studies reported in full text, those published as an abstract only and unpublished data. We excluded studies with a cross‐over design, due to the carry‐over effects of the intervention. </p> </section> <section id="CD013506-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults aged 35 years and over with acute exacerbations of COPD (defined as a worsening of a previously stable condition with increasing respiratory symptoms, particularly dyspnoea, cough, sputum production and increased sputum purulence). We included studies where diagnosis of COPD was physician‐diagnosed or guideline‐based, according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) (<a href="./references#CD013506-bbs2-0059" title="2021 Global Strategy for Prevention, Diagnosis and Management of COPD. goldcopd.org/2021-gold-reports/ (accessed 30 September 2021).">GOLD 2021</a>), the American Thoracic Society (ATS) and European Respiratory Society (ERS) (<a href="./references#CD013506-bbs2-0036" title="QaseemA , WiltTJ , WeinbergerSE , HananiaNA , CrinerG , van derMolenT , et al.Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155(3):179–91.">ATS/ERS 2011</a>), the Thoracic Society of Australia and New Zealand (TSANZ) (<a href="./references#CD013506-bbs2-0109" title="YangIA , BrownJL , GeorgeJ , JenkinsS , McDonaldCF , McDonaldV , et al.The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2019. Version 2.59, August 2019. copdx.org.au/copd-x-plan/.">Yang 2019</a>), or the UK National Institute for Health and Care Excellence (NICE) (<a href="./references#CD013506-bbs2-0089" title="National Institute for Health and Care Excellence.Chronic obstructive pulmonary disease in over 16s: diagnosis and management. www.guidelines.co.uk/respiratory/nice-copd-guideline/454912.article (accessed 8 December 2019).">NICE 2019</a>). </p> <p>We planned to include trials that assessed participants with mixed COPD and asthma features (asthma‐COPD overlap, ACO), based on the consensus published by the Global Initiative for Asthma (GINA) and GOLD (<a href="./references#CD013506-bbs2-0060" title="Global Initiative for Asthma, Global Initiative for Chronic Obstructive Lung Disease.Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS); 2015. goldcopd.org/asthma-copd-asthma-copd-overlap-syndrome.">GOLD ACO 2015</a>), provided that the trials reported outcomes separately for the different participant groups. We excluded participants with the following comorbidities or characteristics: pneumothorax, bronchiectasis, cystic fibrosis, other chronic lung diseases or heart failure. </p> <p>If we found trials in which only a subset of participants had a diagnosis of COPD, we had planned to include these participants if we could obtain disaggregated data from the trial authors. We also planned to include studies that recruited participants with other pulmonary diseases, provided the results of a subset of participants with COPD were available to extract separately. However, we did not encounter such studies. </p> </section> <section id="CD013506-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared magnesium sulfate (irrespective of dose and route of administration, such as intravenous or inhalation), as an adjunct to standard therapy for acute exacerbation of COPD. </p> <p>We compared magnesium sulfate with standard therapy (ipratropium bromide), or with a placebo. We allowed standard therapy as co‐interventions, provided that they were not part of the randomised treatment: e.g. systemic corticosteroids; antibiotics; short‐acting bronchodilators, such as salbutamol or ipratropium bromide; mucolytics; intravenous aminophylline or oxygen therapy. </p> <p>For intravenous magnesium sulfate, we studied the following comparisons.</p> <p> <ol id="CD013506-list-0001"> <li> <p>Intravenous magnesium sulfate + standard care versus placebo + standard care</p> </li> <li> <p>Intravenous magnesium sulfate + standard care versus standard care</p> </li> </ol> </p> <p>For inhaled/nebulised magnesium sulfate, we studied the following comparisons.</p> <p> <ol id="CD013506-list-0002"> <li> <p>Inhaled magnesium sulfate + standard care versus placebo + standard care</p> </li> <li> <p>Inhaled magnesium sulfate + standard care versus standard care</p> </li> </ol> </p> </section> <section id="CD013506-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Primary and secondary outcomes of this review are as follows.</p> <section id="CD013506-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013506-list-0003"> <li> <p>Proportion of people with hospital admissions (from the emergency room)</p> </li> <li> <p>Proportion of people requiring non‐invasive ventilation (NIV), assisted ventilation or admission to intensive‐care unit (ICU) </p> </li> <li> <p>Proportion of people with serious adverse events</p> </li> </ol> </p> </section> <section id="CD013506-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013506-list-0004"> <li> <p>Length of hospital stay (inpatients) or time to emergency room discharge (outpatients)</p> </li> <li> <p>Proportion of people with all‐cause mortality</p> </li> <li> <p>Proportion of people with adverse events/side effects</p> </li> <li> <p>Arterial‐blood gas measurements: arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>), arterial partial pressure of oxygen (PaO<sub>2</sub>) and pH </p> </li> <li> <p>Lung function measurements: forced expiratory volume in the first second (FEV<sub>1</sub>), if available, or peak expiratory flow rate (PEFR) if the trial did not report FEV<sub>1</sub> </p> </li> <li> <p>Symptom scores measuring breathlessness, cough and sputum production using validated scales; e.g. Exacerbations of Chronic Pulmonary Disease Tool (EXACT) total score </p> </li> </ol> </p> <p>If the trial measured arterial‐blood gas, lung function and symptom scores at multiple time points, we used the data at (or as close as possible to) 60 minutes postbaseline for meta‐analysis. We chose this time point as we expected that most participants will have a response to treatment within an hour, and to maximise the homogeneity of pooled results. Reporting one or more of the outcomes listed here in the study was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD013506-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013506-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified studies from searches of the following databases and trial registries up to 2 August 2021, with no restriction on language or type of publication: </p> <p> <ol id="CD013506-list-0005"> <li> <p>Cochrane Airways Trials Register (<a href="./references#CD013506-bbs2-0044" title="Cochrane Airways Trials Register. airways.cochrane.org/trials-register (accessed 7 May 2019).">Cochrane Airways 2019</a>), via the Cochrane Register of Studies, all years to date; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), via the Cochrane Register of Studies, all years to date; </p> </li> <li> <p>MEDLINE OvidSP, 1946 to date;</p> </li> <li> <p>Embase OvidSP, 1974 to date;</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>); </p> </li> <li> <p>EU Clinical Trials Register;</p> </li> <li> <p>Iranian Registry of Clinical Trials.</p> </li> </ol> </p> <p>The search strategies for each database are in <a href="./appendices#CD013506-sec-0104">Appendix 1</a>. The Cochrane Airways Information Specialist developed and conducted the searches, in collaboration with the authors. We followed the Cochrane guidance for developing search strategies and applying study design filters (<a href="./references#CD013506-bbs2-0079" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al.Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2021</a>). </p> <p>Searches of the Cochrane Airways Trials Register and the CENTRAL database incorporated handsearched conference abstracts and grey literature. </p> </section> <section id="CD013506-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We also searched on PubMed for errata or retractions from included studies published in full text, on 8 November 2021. </p> </section> </section> <section id="CD013506-sec-0026"> <h3 class="title" id="CD013506-sec-0026">Data collection and analysis</h3> <section id="CD013506-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HN and SZA) screened the titles and abstracts of the search results independently, and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full‐text study reports of all potentially eligible studies, and two review authors (HN and SZA) independently screened them for inclusion, recording the reasons for exclusion of ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third review author (CN). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, is the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and characteristics of excluded studies table (<a href="./references#CD013506-bbs2-0085" title="MoherD , LiberatiA , TetzlaffJ , AltmanD .Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]">Moher 2009</a>). </p> </section> <section id="CD013506-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which we used as a pilot on one study in the review. Two review authors (HN and SZA) extracted the following study characteristics from the included studies. </p> <p> <ul id="CD013506-list-0006"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, withdrawals and date of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for studies and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (HN and SZA) independently extracted outcome data from included studies. We added notes in the characteristics of included studies table if a trial did not report outcome data in a usable way. We resolved disagreements by consensus as well as by involving a third review author (CN). One review author (HN) transferred data into the Review Manager file (<a href="./references#CD013506-bbs2-0092" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>) or <a href="./references#CD013506-bbs2-0093" title="Review Manager Web (RevMan Web).Version 4.6.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>. We double‐checked that we entered the data correctly by comparing the data presented in the systematic review with the study reports. A second review author (SZA) spot‐checked study characteristics for accuracy against the study report. </p> </section> <section id="CD013506-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HN and SZA) assessed risk of bias independently for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013506-bbs2-0067" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). We resolved any disagreements by discussion as well as by involving another author (CN). We assessed the risk of bias according to the following domains: </p> <p> <ol id="CD013506-list-0007"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <p>We judged each potential source of bias as high, low or unclear, and provided a quote from the study report together with a justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different from a participant‐reported pain scale). Where information on risk of bias related to unpublished data or correspondence with a trialist, we included a note in the risk of bias table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies which contributed to that outcome. </p> <section id="CD013506-sec-0030"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and justified any deviations from it in the <a href="#CD013506-sec-0117">Differences between protocol and review</a> section of this systematic review. </p> </section> </section> <section id="CD013506-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (OR) and continuous data as the mean difference (MD) or standardised mean difference (SMD). For rare events, we used Peto ORs. When we combined data from rating scales in a meta‐analysis, we ensured that we entered these with a consistent direction of effect (e.g. lower scores always indicate improvement). </p> <p>We undertook meta‐analyses only where this was meaningful; that is, if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. </p> <p>We described skewed data narratively (for example, as medians and interquartile ranges for each group). </p> <p>If a trial reported both change‐from‐baseline and endpoint scores for continuous data, we used change‐from‐baseline data. If a study reported outcomes at multiple time points, we used the data collected at or as close as possible to 60 minutes postbaseline. </p> <p>We used intention‐to‐treat (ITT) or 'full analysis set' analyses where trials reported these (i.e. those where trialists had imputed data for participants who were randomly assigned, but did not complete the study), instead of completer or per‐protocol analyses. </p> </section> <section id="CD013506-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we used participants, rather than events, as the unit of analysis (i.e. the number of participants with a hospital admission rather than the number of admissions per participant). We planned to analyse on the basis of events rather than participants if a trial reported rate ratios; however, none of the included studies in this review used rate ratios. </p> <p>Where a single study reported multiple trial arms, we included only the relevant arms. If we combined two comparisons in the same meta‐analysis (e.g. intravenous magnesium sulfate versus placebo and inhaled magnesium sulfate versus placebo), we halved the control group to avoid double‐counting. </p> </section> <section id="CD013506-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when we only identified a study as an abstract). Where this was not possible, and we thought the missing data could introduce serious bias, we took this into consideration in the GRADE rating for affected outcomes. </p> </section> <section id="CD013506-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the studies in each analysis, and interpreted this following <a href="./references#CD013506-bbs2-0067" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>, as: </p> <p> <ul id="CD013506-list-0008"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When we identified substantial heterogeneity (I² &gt; 50%), we reported it and explored the possible causes by prespecified subgroup analysis. </p> </section> <section id="CD013506-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to create and examine a funnel plot to explore possible small study and publication biases if we were able to pool more than 10 studies (<a href="./references#CD013506-bbs2-0067" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). Though we identified 11 included studies, most analyses in this review included only one or two studies. </p> </section> <section id="CD013506-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model, and performed a sensitivity analysis with a fixed‐effect model. As we gathered data from a series of studies performed by different researchers operating independently, the studies were not all functionally equivalent with a common effect estimate. Therefore, the random‐effects model was more justified than the fixed‐effect model. We used a fixed‐effect model for analyses using the Peto OR method as it required this type of model. </p> </section> <section id="CD013506-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to carry out the following subgroup analyses:</p> <p> <ol id="CD013506-list-0009"> <li> <p>concomitant treatment with systemic corticosteroids (yes versus no);</p> </li> <li> <p>blood eosinophil count (≥ 300/µL versus &lt; 300/µL);</p> </li> <li> <p>COPD versus asthma‐COPD overlap</p> </li> </ol> </p> <p>In each subgroup analysis, we had planned to use the following outcomes:</p> <p> <ol id="CD013506-list-0010"> <li> <p>need for admission to hospital (from the emergency department);</p> </li> <li> <p>need for NIV, assisted ventilation or admission to ICU;</p> </li> <li> <p>length of hospital stay (inpatients) or time to emergency room discharge (outpatients).</p> </li> </ol> </p> <p>However, we were unable to carry out subgroup analyses as none of the included trials reported data separately for the planned subgroups. </p> </section> <section id="CD013506-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We included all trials, irrespective of risk of bias, in the primary analysis.</p> <p>We had planned to carry out the following sensitivity analyses for the primary outcomes:</p> <p> <ol id="CD013506-list-0011"> <li> <p>removing studies with unclear or high risk of performance or detection bias due to lack of appropriate blinding; </p> </li> <li> <p>comparing the results from inclusion and exclusion of imputed data values;</p> </li> <li> <p>comparing the results from a fixed‐effect model with those from a random‐effects model.</p> </li> </ol> </p> <p>However, we did not carry out these sensitivity analyses as they were not applicable for this review. </p> </section> <section id="CD013506-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created three summary of findings tables, one for each comparison, using the following outcomes: </p> <p> <ol id="CD013506-list-0012"> <li> <p>proportion of people with hospital admissions (from the emergency room);</p> </li> <li> <p>proportion of people requiring non‐invasive ventilation, endotracheal intubation, ventilatory support (NIV or assisted ventilation) or ICU admission; </p> </li> <li> <p>proportion of people with serious adverse events;</p> </li> <li> <p>length of hospital stay;</p> </li> <li> <p>change in oxygen saturation (SaO<sub>2</sub>/SpO<sub>2</sub>); </p> </li> <li> <p>change in dyspnoea score;</p> </li> <li> <p>lung function: FEV1 at 60 min.</p> </li> </ol> </p> <p>We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence in relation to the studies that contributed data for the prespecified outcomes. We used the methods and recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013506-bbs2-0097" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Schünemann 2021</a>), using GRADEpro software (<a href="./references#CD013506-bbs2-0062" title="GRADEpro GDT.Version accessed 30 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to downgrade the quality of studies using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013506-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013506-sec-0040"></div> <section id="CD013506-sec-0041"> <h3 class="title">Description of studies</h3> <p>Refer to <a href="./references#CD013506-sec-0119" title="">Characteristics of included studies</a>; <a href="./references#CD013506-sec-0120" title="">Characteristics of excluded studies</a> and <a href="./references#CD013506-sec-0121" title="">Characteristics of ongoing studies</a> for details. </p> <section id="CD013506-sec-0042"> <h4 class="title">Results of the search</h4> <p>We performed an initial search of the databases (Cochrane Airways Group Register of trials, CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, WHO ICTRP) in December 2019, an updated search in April 2021, and authors updated the search in August 2021. We also searched the reference lists of all primary studies and review articles. From the search, we identified a total of 376 records, of which 127 were duplicates. We screened the titles and abstracts of the remaining 249 records, out of which we excluded 207 reports. We assessed 42 full‐text articles for eligibility and excluded 18 studies (23 references). One trial was ongoing, and 11 studies (18 references) met the inclusion criteria of our review. For details of the search results, see <a href="#CD013506-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013506-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013506-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD013506-sec-0043"> <h4 class="title">Included studies</h4> <p>For details, see <a href="./references#CD013506-sec-0119" title="">Characteristics of included studies</a> and <a href="#CD013506-tbl-0004">Table 1</a>. </p> <div class="table" id="CD013506-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study centres</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study location</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number randomised</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concomitant treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hospitalisations<br/>in the last 12<br/>months, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ICU admission in the last 12<br/>months</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serum magnesium level:</b> mean (SD) </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised MgSO<sub>4</sub> + Nebulised salbutamol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + nebulised salbutamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen, ipratropium, hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised MgSO<sub>4</sub> + standard care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen, steroids, antibiotics and ipratropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO<sub>4</sub>: 3 (30) </p> <p>Placebo: 4 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4: 0</p> <p>Placebo: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised MgSO<sub>4</sub> + Nebulised salbutamol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + nebulised salbutamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO<sub>4</sub>: 1 </p> <p>Placebo: 1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mmol/L</p> <p>MgSO<sub>4</sub>: 0.81 (0.08) </p> <p>Placebo: 0.78 (0.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen, inhaled salbutamol and ipratropium, intravenous hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen, nebulised salbutamol, nebulised<br/>ipratropium, IV hydrocortisone, IV antibiotics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised salbutamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mmol/L</p> <p>MgSO<sub>4</sub>: 0.79 (0.1) </p> <p>Placebo: 0.78 (0.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tunisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised MgSO<sub>4</sub> + IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised ipratropium + IV normal saline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV methyl prednisolone, antibiotics,<br/>and nebulised terbutaline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO<sub>4</sub>: 3.6 (2.4) </p> <p>Ipratropium: 3.1 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion + standard care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised albuterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mmol/L</p> <p>MgSO<sub>4</sub>: 0.94 (0.16) </p> <p>Placebo: 0.98 (0.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion + standard treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bronchodilators, oxygen, corticosteroid and antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO<sub>4</sub>: 9 (60)<br/>Placebo: 10 (67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mEq/L</p> <p>MgSO<sub>4</sub>: 2.11 (0.28) </p> <p>Placebo: 2.05 (0.40)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: MgSO<sub>4</sub>: magnesium sulfate; NR: not reported </p> </div> </div> <section id="CD013506-sec-0044"> <h5 class="title">Study Design</h5> <p>Ten included studies were double‐blind randomised controlled trials that assessed magnesium sulfate in COPD exacerbations, while one study was a single‐blind RCT (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>). Eight studies were single‐centre trials (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>). These were conducted in Iran (<a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>), New Zealand (<a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>), Nepal (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>), Turkey (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>) and the UK (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>). The other three trials were conducted at two centres in New Zealand (<a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>), Tunisia (<a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>), and the USA (<a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>). The dates of study were not available for four trials (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>), while the other studies were performed between 2004 and 2018. </p> </section> <section id="CD013506-sec-0045"> <h5 class="title">Participants</h5> <p>The studies randomised a total of 762 participants; <a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> was the largest trial with 172 participants, while <a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a> was the smallest with only 20 participants. The studies included male and female adult participants over 35 years old, with a mean age range from 62 to 76 years. Participants had clinically diagnosed COPD and presented with an exacerbation, precipitated by either infection or non‐infective causes. Definitions for acute exacerbations were mentioned in four studies (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>), while other trials did not specify these (refer to <a href="./references#CD013506-sec-0119" title="">Characteristics of included studies</a> for details). Participants presenting to the emergency department were included in all trials except <a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>, which included hospital inpatients. None of the trials classified the severity of COPD exacerbations. </p> </section> <section id="CD013506-sec-0046"> <h5 class="title">Interventions</h5> <p>Seven trials assessed intravenous magnesium sulfate infusion plus standard care versus placebo plus standard care (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>). Three trials studied nebulised magnesium sulfate plus standard care versus placebo plus standard care (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>). <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a> studied nebulised magnesium sulfate plus intravenous magnesium sulfate versus nebulised ipratropium bromide plus intravenous normal saline. Participants in all trials received standard initial treatment before allocation to intervention arms. The standard care included supplemental oxygen via nasal cannula, nebulised salbutamol or ipratropium bromide, or both. In eight trials they also received systemic corticosteroids (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>). Participants in four studies received antibiotics (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>). </p> <p>The dose of magnesium sulfate was 1.2 to 2.0 g infused over 20 minutes, except in <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a> where 2.5 g was infused over 15 minutes. For inhaled magnesium sulfate, the dose administered was 150 mg per dose. Magnesium was administered 20 minutes after initial standard treatment with no improvement in lung function in four trials (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>). It was administered concurrently or immediately after the standard therapy in three trials (<a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>). <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a> reported that magnesium was given within the first 60 minutes of standard therapy. There was no information on timing of magnesium administration in the remaining three studies (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>). </p> </section> <section id="CD013506-sec-0047"> <h5 class="title">Comparison</h5> <p>With the exception of <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>, all trials compared intervention to placebo, with both arms receiving standard care. <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a> compared magnesium sulfate (both nebulised and IV) with nebulised ipratropium bromide and IV normal saline. </p> </section> <section id="CD013506-sec-0048"> <h5 class="title">Primary outcomes</h5> <p>Four trials reported the proportion of participants who needed hospital admission (<a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>), and five reported the proportion of participants who need NIV, mechanical ventilation or ICU admission as one of their outcomes (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>). </p> </section> <section id="CD013506-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p>Length of hospital stay was reported in four trials (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>), while only two studies reported hospital death rate (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>). Arterial blood gas was one of the outcomes in four trials (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>). Most trials measured lung function as a primary outcome; five trials reported FEV<sub>1</sub> (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>); and six reported PEFR (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>. The trials measured dyspnoea score in various ways: a visual analogue scale (VAS) dyspnoea score (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>); Borg dyspnoea score (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>); dyspnoea severity score (DSS) score (<a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>) and unspecified (<a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>). </p> </section> <section id="CD013506-sec-0050"> <h5 class="title">Funding</h5> <p>Included studies were funded by the researcher (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>), affiliated universities (<a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>), or local health councils (<a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>). There was no information on funding for the other four trials (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>). </p> </section> </section> <section id="CD013506-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 18 trials during the full‐text review; six trials assessed the effect of magnesium in people with stable COPD (<a href="./references#CD013506-bbs2-0013" title="ACTRN12608000502336.Effects of inhaled magnesium on pulmonary function and walking distance of patients with stable chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83127 (first received 3 September 2008). ">ACTRN12608000502336</a>; <a href="./references#CD013506-bbs2-0014" title="AhmedA , SayedAH , ElkholyJ , ElshalS , BadwyA , AbdelhamidB , et al.Intraoperative MgSO4 infusion protects oxygenation and lung mechanics in COPD patients during general anaesthesia. A randomised clinical trial. Acta Anaesthesiologica Scandinavica2020;64(10):1460-8. ">Ahmed 2020</a>; <a href="./references#CD013506-bbs2-0015" title="AmaralAF , Gallo L Jr, VannucchiH , CrescencioJC , ViannaEO , MartinezJA .The effect of acute magnesium loading on the maximal exercise performance of stable chronic obstructive pulmonary disease patients. Clinics2012;67(6):615-22. [PMID: 22760901]AmaralAF , Rodrigues-JuniorAL , Terra FilhoJ , VannucchiH , MartinezJA .Effects of acute magnesium loading on pulmonary function of stable COPD patients. Medical Science Monitor2008;14(10):CR524-9. BaddiniMJ , do AmaralAF , CrescencioJC , VannucchiH , ViannaEO , GalloL .Effects of acute magnesium loading on maximal exercise performance of stable COPD patients. ATS Journals2012;185:A1543. MartinezJA , AmaralAF , TeixeiraCA , GalloL , Terra FilhoJ , KazukiRT .The effects of intravenous magnesium loading on pulmonary function of COPD patients in stable clinical conditions. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007. NCT00500864.Magnesium loading in chronic obstructive pulmonary disease [Effects of acute intravenous magnesium loading on pulmonary function parameters and maximal exercise capacity of patients with chronic obstructive pulmonary disease in stable clinical conditions]. clinicaltrials.gov/ct2/show/NCT00500864 (first received 13 July 2007). ">Amaral 2012</a>; <a href="./references#CD013506-bbs2-0023" title="NCT01118936.Daily magnesium-treatment of patients with chronic obstructive pulmonary disease [Daily mablet-treatment of patients with COPD]. clinicaltrials.gov/ct2/show/NCT01118936 (first received 7 May 2010). ">NCT01118936 2010</a>; <a href="./references#CD013506-bbs2-0025" title="NCT02680769.Effect of magnesium supplementation in COPD [Daily supplementation of magnesium citrate in moderate-severe chronic obstructive pulmonary disease: a randomised, controlled, double-blind trial]. clinicaltrials.gov/ct2/show/NCT02680769 (first received 12 February 2016). ">NCT02680769 2016</a>; <a href="./references#CD013506-bbs2-0029" title="TagayaE , TamaokiJ , KawataniK , NagaiA .The effect of isotonic nebulized magnesium sulfate on pulmonary function in moderate to severe COPD. In: American Thoracic Society 100th international conference; 2004 May 21-26; Orlando. 2004. ">Tagaya 2004</a>), five studies were not RCTs (<a href="./references#CD013506-bbs2-0016" title="CTRI/2018/01/011354.A study to compare and know the beneficial role of intravenous magnesium sulfate vs placebo as an add on therapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease [A prospective study to compare the efficacy of I.V Magnesium sulfate infusion vs. placebo, as an adjuvant to nebulised salbutamol in acute exacerbations of chronic obstructive pulmonary disease]. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/01/011354 (first received 16 January 2018). ">CTRI/2018/01/011354 2018</a>; <a href="./references#CD013506-bbs2-0017" title="CTRI/2018/04/013309.A study to compare the costs between intravenous Magnesium Sulfate and placebo in acute exacerbations of chronic obstructive pulmonary disease [A prospective study to compare the cost effectiveness of i.v. magnesium sulfate infusion vs. Placebo, as adjutant to nebulised salbutamol in acute exacerbations of chronic obstructive pulmonary disease.]. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/04/013309 (first received 17 April 2018). ">CTRI/2018/04/013309 2018</a>; <a href="./references#CD013506-bbs2-0021" title="JennerR , BodyR .Best evidence topic report. Intravenous magnesium in chronic obstructive pulmonary disease. Emergency Medicine Journal2004;21(2):203. ">Jenner 2004</a>; <a href="./references#CD013506-bbs2-0026" title="SchenkP , VonbankK , SchnackB , HaberP , Lehr St, SmetanaR .Magnesium in obstructive respiratory tract disease. Journal fur Mineralstoffwechsel2001;8(3):38-41. ">Schenk 2001</a>; <a href="./references#CD013506-bbs2-0028" title="SternfeldM , ElirazA .Magnesium and obstructive lung diseases. Harefuah1994;126(11):681-3. ">Sternfeld 1994</a>), two trials were withdrawn (<a href="./references#CD013506-bbs2-0020" title="EUCTR2006-002484-99-GB.The use of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease (COPD) - nebulised magnesium in COPD. www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2006-002484-99-GB (first received 10 January 2007). ISRCTN65174202.The use of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN65174202 (first received 4 December 2006). ">ISRCTN65174202 2006</a>; <a href="./references#CD013506-bbs2-0024" title="NCT02498496.Magnesium sulfate to prevent hospitalisation of acute exacerbations of chronic obstructive pulmonary disease [MASTER-ED: magnesium sulfate to prevent hospitalisation of acute exacerbations of chronic obstructive pulmonary disease seen in the emergency department]. clinicaltrials.gov/ct2/show/NCT02498496 (first received 15 July 2015). ">NCT02498496 2015</a>), another two were of cross‐over design (<a href="./references#CD013506-bbs2-0012" title="Abreu GonzalezJ , Hernandez GarciaC , Abreu GonzalezP , Martin GarciaC , JimenezA .Effect of intravenous magnesium sulfate on chronic obstructive pulmonary disease exacerbations requiring hospitalisation: a randomised placebo-controlled trial. Archivos de Bronconeumologia2006;42(8):384-7. ">Abreu 2006</a>; <a href="./references#CD013506-bbs2-0022" title="MarinoP , BelloliE , InvernizziF .Magnesium sulfate in chronic obstructive pulmonary disease. In: European Respiratory Society 9th Annual Congress; 1999 Oct 9-13; Madrid. 1999. ">Marino 1999</a>), one studied magnesium aspartate (<a href="./references#CD013506-bbs2-0019" title="FriemannEF , LaschHG , FriemannS , GolfS , EnzingerD , TemmeH , et al.Effect of a magnesium therapy on chronic obstructive lung diseases. Die Medizinische Welt1991;42:311-5. ">Friemann 1991</a>), one trial had no magnesium monotherapy arm (<a href="./references#CD013506-bbs2-0027" title="SkorodinM , ShortenJ , LyonK , SmallwoodJ , OwenW , EmeryL , et al.Magnesium sulfate and ipratropium bromide combination in the treatment of COPD exacerbations. Archives of Internal Medicine1998;155(5):496-500. ">Skorodin 1998</a>), and another study assessed inhaled magnesium sulfate versus alpha chymotrypsin atomisation inhalation (<a href="./references#CD013506-bbs2-0018" title="FanMS , WuWH , ChenJY .Effect of magnesium sulfate and oxygen inhalation on pulmonary function in elderly chronic obstructive pulmonary disease during acute attack. Journal of Tropical Medicine2015;15:959-62. ">Fan 2015</a>). See <a href="./references#CD013506-sec-0120" title="">Characteristics of excluded studies</a> for details. </p> </section> </section> <section id="CD013506-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>Refer to <a href="#CD013506-fig-0002">Figure 2</a> for an overview of risk of bias assessment for the included studies. Support for judgements for individual domains are presented in <a href="./references#CD013506-sec-0119" title="">Characteristics of included studies</a> tables. </p> <div class="figure" id="CD013506-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD013506-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD013506-sec-0053"> <h4 class="title">Allocation</h4> <p>Of the 11 included studies, we judged five to be of low risk of bias for random sequence generation (<a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>); the remaining six studies had an unclear risk for this domain due to limited information about how the randomisation process was performed. Six studies reported allocation concealment methods (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>). The other trials gave no further information, so we judged them to have an unclear risk for this domain. </p> </section> <section id="CD013506-sec-0054"> <h4 class="title">Blinding</h4> <p>Ten included studies were double‐blind RCTs, where participants and investigators were unaware of the intervention arm they were involved in (performance bias). However, only seven trials reported detailed process of blinding with low risk of performance bias. <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a> did not provide details, while <a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a> and <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a> were available as abstracts only, and we judged these to be at unclear risk. <a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> was a single‐blind study where the investigator was aware of the assignment; we judged this to be of high risk. Blinding of outcome assessors (detection bias) was at low risk of bias for four studies (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>), and unclear for seven studies due to limited information (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>). </p> </section> <section id="CD013506-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>We rated eight studies to have a low risk of attrition bias: six studies had no dropouts (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>), and two had a low attrition rate (<a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>). We considered the remaining three studies to be at unclear risk due to limited information (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>), or no details about the breakdown of dropouts across the intervention arms though the total number lost to follow‐up was reported (<a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>). </p> </section> <section id="CD013506-sec-0056"> <h4 class="title">Selective reporting</h4> <p>Three studies had a low risk of bias for selective reporting because the trial protocol was available on registries and all outcomes were reported as planned (<a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>; <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>). We considered the other studies to be at unclear risk for reporting bias for various reasons: trial could not be identified on registry websites (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>); only available as abstract (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>); registered on website with no outcomes provided in the protocol (<a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>); and failed to report one of the outcomes stated in the trial protocol on the registry website (<a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>). </p> </section> <section id="CD013506-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>We assumed that the risk of other bias was likely to be high for <a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a> and <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>, as there were no full‐text publications available and the reason for not publishing was not clear. We did not identify any other potential sources of bias for the remaining studies </p> </section> </section> <section id="CD013506-sec-0058"> <h3 class="title" id="CD013506-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD013506-tbl-0001"><b>Summary of findings 1</b> Intravenous magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</a>; <a href="./full#CD013506-tbl-0002"><b>Summary of findings 2</b> Nebulised magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</a>; <a href="./full#CD013506-tbl-0003"><b>Summary of findings 3</b> Magnesium sulfate compared to standard care (ipratropium bromide) for acute exacerbations of chronic obstructive pulmonary disease</a> </p> <p>See <a href="./full#CD013506-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013506-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD013506-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD013506-sec-0059"> <h4 class="title">1. Intravenous magnesium sulfate + standard care compared to placebo + standard care</h4> <section id="CD013506-sec-0060"> <h5 class="title">Proportion of people with hospital admissions (from the emergency room)</h5> <p>Three studies (170 participants) reported the number of participants who needed hospital admission from the emergency room. The result of the analysis suggests a reduction in hospitalisation with intravenous magnesium sulfate compared to placebo (OR 0.45, 95% CI 0.23 to 0.88; I<sup>2</sup> = 0%; <a href="./references#CD013506-fig-0003" title="">Analysis 1.1</a>). In absolute terms, there was a reduction of 197 participants per 1000 with magnesium sulfate infusion compared to placebo for hospital admissions (95% CI 31 lower to 342 lower); the number needed to treat for an additional beneficial outcome (NNTB) is seven. Using GRADE, we judged the certainty of the evidence to be low due to serious concerns about study limitations and imprecision due to few events. </p> </section> <section id="CD013506-sec-0061"> <h5 class="title">Proportion of people needing non‐invasive ventilation, assisted ventilation or admission to intensive care unit </h5> <p>The need for NIV and endotracheal intubation was reported by <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>and <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>, but no trial assessed ICU admission. The pooled analysis for NIV indicated no evidence of a difference between magnesium and placebo arms (OR 0.74, 95% CI 0.31 to 1.75; I<sup>2</sup> = 0%; <a href="./references#CD013506-fig-0004" title="">Analysis 1.2</a>). We graded the level of certainty as very low due to concerns over study limitations and imprecision. There were no people who needed endotracheal intubation in either the magnesium or placebo groups in either of the studies (107 participants). </p> </section> <section id="CD013506-sec-0062"> <h5 class="title">Proportion of people with serious adverse events</h5> <p>There were no reported serious adverse events for magnesium and placebo groups in <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a> (77 participants). Other trials did not assess this outcome. </p> </section> <section id="CD013506-sec-0063"> <h5 class="title">Length of hospital stay (inpatients) or time to emergency room discharge (outpatients)</h5> <p>Two trials (54 participants) reported on the length of hospital stay for inpatients (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>), but no study assessed time to discharge from the emergency room. There was a mean difference in favour of magnesium infusion of ‐2.70 days (95% CI ‐4.73 to ‐0.66; I<sup>2</sup> = 0%; <a href="./references#CD013506-fig-0005" title="">Analysis 1.3</a>). Using GRADE, we downgraded the certainty of evidence by two levels to low due to concerns over study limitations (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a> is available as abstract only) and imprecision (few events). </p> </section> <section id="CD013506-sec-0064"> <h5 class="title">Proportion of people with all‐cause mortality</h5> <p>No study reported this outcome.</p> </section> <section id="CD013506-sec-0065"> <h5 class="title">Proportion of people with adverse events/side effects</h5> <p><a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a> and <a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a> reported on adverse events, with no adverse events in the magnesium group in either of the trials. However, four participants in the placebo arm reported adverse events; one had a flushing feeling in the hands and face (<a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>), and three experienced nausea and weakness, dizziness and increased secretions (<a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>). Though the Peto odds ratio was 0.14 (95% CI 0.02 to 1.00; I<sup>2</sup> = 0%; 102 participants; <a href="./references#CD013506-fig-0006" title="">Analysis 1.4</a>), the small number of participants and low event rate limit our confidence in conclusions. </p> </section> <section id="CD013506-sec-0066"> <h5 class="title">Arterial‐blood gas measurements</h5> <p>No study measured arterial‐blood gas (ABG) values. However, <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a> (77 participants) reported the change in oxygen saturation (SaO<sub>2</sub>). <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a> also assessed oxygen saturation before and 45 minutes after the intervention, but change from baseline data values were not available to be included in the analysis. The mean difference was 0.32% (95% CI ‐1.53 to 2.17; <a href="./references#CD013506-fig-0007" title="">Analysis 1.5</a>), indicating little to no difference between the groups. We graded the certainty of evidence as very low due to concerns over study limitations and very serious imprecision (few events and the confidence interval includes both appreciable benefit and appreciable harm). </p> </section> <section id="CD013506-sec-0067"> <h5 class="title">Lung function measurements</h5> <p><a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a> assessed change from baseline in FEV<sub>1</sub> at 60 minutes, whereas <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a> reported post‐intervention FEV<sub>1</sub> at 45 minutes. Two studies measured PEFR in L/min (<a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a>; <a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a>), and <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a> reported change in PEFR as percentage of predicted value. </p> <p>There was a mean difference of 0.00 L (95% CI ‐0.04 to 0.05) for change in FEV<sub>1</sub> at 60 minutes, indicating no evidence of a difference between the interventions (<a href="./references#CD013506-fig-0008" title="">Analysis 1.6</a>). Using GRADE, we downgraded the certainty of evidence two levels to low due to very serious imprecision as the confidence interval includes both appreciable benefit and appreciable harm and few events. </p> <p>Post‐intervention FEV<sub>1</sub> was not different between intravenous magnesium and placebo at 45 minutes (MD 2.10 mL, 95% CI ‐0.89 to 5.09; <a href="./references#CD013506-fig-0009" title="">Analysis 1.7</a>). </p> <p>Similarly, no evidence of a difference was noted between magnesium and placebo for the change in PEFR (MD 9.12 L/min, 95% CI ‐6.20 to 24.44; I<sup>2</sup> = 56%; 102 participants; <a href="./references#CD013506-fig-0010" title="">Analysis 1.8</a>). However, for the change in PEFR % predicted, there was a mean difference of 10.64 % predicted (95% CI 8.38 to 12.90), in favour of magnesium sulfate infusion (<a href="./references#CD013506-fig-0011" title="">Analysis 1.9</a>). </p> </section> <section id="CD013506-sec-0068"> <h5 class="title">Symptom scores measuring breathlessness, cough and sputum production using validated scales </h5> <p>Symptom score was measured in three trials using different validated scales; DSS score in <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>, and Borg dyspnoea score in <a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a>. Data for change in dyspnoea score from baseline for individual intervention arms was not available for <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a> so we could not include it in the analysis. There was a reduction in dyspnoea score, with a standardised mean difference of ‐1.40 (95% CI ‐1.83 to ‐0.96; I<sup>2</sup> = 0%; 101 participants; <a href="./references#CD013506-fig-0012" title="">Analysis 1.10</a>), indicating a difference in favour of magnesium infusion. We graded the level of certainty for this as low due to concerns over study limitations and imprecision (few events). </p> </section> </section> <section id="CD013506-sec-0069"> <h4 class="title">2. Nebulised magnesium sulfate + standard care compared to placebo + standard care</h4> <section id="CD013506-sec-0070"> <h5 class="title">Proportion of people with hospital admissions (from the emergency room)</h5> <p><a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a> reported hospital admissions in 109 participants. There was little to no difference between the groups (OR 0.77, 95% CI 0.21 to 2.82). We graded the certainty of evidence as very low due to concerns over study limitations and very serious imprecision as the confidence interval includes both appreciable benefit and appreciable harm (<a href="./references#CD013506-fig-0013" title="">Analysis 2.1</a>). </p> </section> <section id="CD013506-sec-0071"> <h5 class="title">Proportion of people needing non‐invasive ventilation, assisted ventilation or admission to intensive care unit </h5> <p>Two studies reported ICU admissions (<a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>), with no events in the study by <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>. With 281 participants, magnesium inhalation may be associated with fewer ICU admissions compared to placebo (OR 0.39, 95% CI 0.15 to 1.00; <a href="./references#CD013506-fig-0014" title="">Analysis 2.2</a>). However, the certainty of evidence was very low as the single‐blinded study <a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> had a high risk of performance bias, and there were few events. </p> <p>There was little to no difference between nebulised magnesium and placebo in requirement for ventilatory support (either NIV or assisted ventilation) in <a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> (OR 0.33, 95% CI 0.01 to 8.20; 172 participants; <a href="./references#CD013506-fig-0015" title="">Analysis 2.3</a>; very low‐certainty evidence). </p> <p>There were no reported cases of NIV requirement (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; 129 participants) or endotracheal intubation (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>, 20 participants) for magnesium and placebo groups. </p> </section> <section id="CD013506-sec-0072"> <h5 class="title">Proportion of people with serious adverse events</h5> <p>There were no serious adverse events for magnesium and placebo groups (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>, 20 participants). </p> </section> <section id="CD013506-sec-0073"> <h5 class="title">Length of hospital stay (inpatients) or time to emergency room discharge (outpatients)</h5> <p><a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a> reported length of hospital stay for inpatients, but no studies reported time to emergency room discharge for outpatients. There was little to no difference between magnesium and placebo groups for the length of hospital stay, with a mean difference of ‐0.80 days (95% CI ‐4.63 to 3.03; <a href="./references#CD013506-fig-0016" title="">Analysis 2.4</a>). The certainty of evidence for this outcome was very low due to concerns over study limitations and very serious imprecision (few events and the confidence interval includes both appreciable benefit and appreciable harm). </p> </section> <section id="CD013506-sec-0074"> <h5 class="title">Proportion of people with all‐cause mortality</h5> <p><a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> reported one death in the placebo arm and no deaths in the magnesium arm. However, the number of participants and the event rate are too small to reach a conclusion (OR 0.33, 95% CI 0.01 to 8.20; <a href="./references#CD013506-fig-0017" title="">Analysis 2.5</a>). There was no report on this outcome in <a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a> and <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>. </p> </section> <section id="CD013506-sec-0075"> <h5 class="title">Proportion of people with adverse events/side effects</h5> <p>There were no reported adverse events for either magnesium or placebo arms (<a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a>; <a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a>; 129 participants). </p> </section> <section id="CD013506-sec-0076"> <h5 class="title">Lung function measurements:</h5> <p><a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a> reported FEV<sub>1</sub> at 60 minutes for 109 participants. There was little to no difference between the groups, with a mean difference of ‐0.05 L (95% CI ‐0.17 to 0.07; <a href="./references#CD013506-fig-0018" title="">Analysis 2.6</a>). We graded the evidence as very low certainty due to study limitations and very serious imprecision (few events and the confidence interval includes both appreciable benefit and appreciable harm). </p> <p><a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a> reported change from baseline in PEFR at 60 minutes in 20 participants, with a mean difference of 7.60 L/min (95% CI ‐4.38 to 19.58) between magnesium and placebo groups, indicating little to no difference between the groups (<a href="./references#CD013506-fig-0019" title="">Analysis 2.7</a>). </p> <p><a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> assessed post‐intervention PEFR at 60 minutes in 172 participants. Magnesium inhalation was associated with a higher PEFR compared to the placebo group, with a mean difference of 7.40 L/min (95% CI 1.81 to 12.99; <a href="./references#CD013506-fig-0020" title="">Analysis 2.8</a>). However, data were too limited for us to be able to reach a conclusion. </p> </section> <section id="CD013506-sec-0077"> <h5 class="title">Symptom scores measuring breathlessness, cough and sputum production using validated scales </h5> <p><a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a> assessed improvement in symptoms using the VAS dyspnoea score in 20 participants, and revealed a mean difference in favour of nebulised magnesium of ‐14.37 points (95% CI ‐26.00 to ‐2.74; <a href="./references#CD013506-fig-0021" title="">Analysis 2.9</a>); the evidence had a very low level of certainty due to concerns over study limitations and small participant numbers. The effect estimate of 14.37 points lower is more than the minimal clinically important difference (MCID) of 10 units for the VAS dyspnoea score (<a href="./references#CD013506-bbs2-0094" title="RiesAL .Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD2005;2(1):105-10. [DOI: 10.1081/copd-200050655] [PMID: 17136970]">Ries 2005</a>). However, the numbers of participants and events were too small to reach a robust conclusion. </p> </section> <section id="CD013506-sec-0078"> <h5 class="title">Arterial‐blood gas measurements:</h5> <p><a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a> reported change in SaO<sub>2</sub> in 20 participants, with a mean difference of ‐1.10 (95% CI ‐4.60 to 2.40), indicating little to no difference between magnesium and placebo (<a href="./references#CD013506-fig-0022" title="">Analysis 2.10</a>). We graded the certainty of evidence for this outcome as very low due to concerns over study limitations and very serious imprecision (few events and the confidence interval includes both appreciable benefit and appreciable harm). </p> </section> </section> <section id="CD013506-sec-0079"> <h4 class="title">3. Magnesium sulfate compared to standard care (ipratropium bromide)</h4> <section id="CD013506-sec-0080"> <h5 class="title">Proportion of people with hospital admissions (from the emergency room)</h5> <p>There was little to no difference between magnesium sulfate and ipratropium bromide for hospital admission (OR 1.62, 95% CI 0.78 to 3.37; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; 124 participants; <a href="./references#CD013506-fig-0023" title="">Analysis 3.1</a>). The certainty of evidence for this outcome was very low due to very serious imprecision (the confidence interval includes both appreciable benefit and appreciable harm, and there were few events), as well as concerns over study limitations. </p> </section> <section id="CD013506-sec-0081"> <h5 class="title">Proportion of people needing non‐invasive ventilation, assisted ventilation or admission to intensive care unit </h5> <p><a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a> reported the need for endotracheal intubation in 124 participants. Analysis indicated little to no difference between the groups (OR 1.69, 95% CI 0.61 to 4.71; <a href="./references#CD013506-fig-0024" title="">Analysis 3.2</a>). We graded the certainty of evidence for this outcome as very low due to very serious imprecision (the confidence interval includes both appreciable benefit and appreciable harm, and there were few events), as well as concerns over study limitations. </p> <p>There was no report on non‐invasive ventilation or admission to ICU.</p> </section> <section id="CD013506-sec-0082"> <h5 class="title">Proportion of people with serious adverse events</h5> <p>There was no report on this outcome.</p> </section> <section id="CD013506-sec-0083"> <h5 class="title">Length of hospital stay (inpatients) or time to emergency room discharge (outpatients)</h5> <p>There was little to no difference in the length of hospital stay between the groups, with a mean difference of 1.10 days (95% CI ‐0.22 to 2.42; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; 124 participants; <a href="./references#CD013506-fig-0025" title="">Analysis 3.3</a>). The certainty of evidence for this outcome was very low due to very serious imprecision (the confidence interval includes both appreciable benefit and appreciable harm, and there were few events), as well as concerns over study limitations. </p> </section> <section id="CD013506-sec-0084"> <h5 class="title">Proportion of people with all‐cause mortality</h5> <p>There was little to no difference between magnesium and ipratropium in all‐cause mortality (OR 0.51, 95% CI 0.05 to 4.97; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; 124 participants; <a href="./references#CD013506-fig-0026" title="">Analysis 3.4</a>), but events were rare (1/62 in the magnesium arm and 2/62 in the control arm). </p> </section> <section id="CD013506-sec-0085"> <h5 class="title">Proportion of people with adverse events/side effects</h5> <p>There was no report on this outcome.</p> </section> <section id="CD013506-sec-0086"> <h5 class="title">Arterial‐blood gas measurements</h5> <p>There was no report on this outcome.</p> </section> <section id="CD013506-sec-0087"> <h5 class="title">Lung function measurements</h5> <p>Improvement in PEFR was reported, favouring ipratropium bromide with a mean difference of 32.00 L/min (95% CI 19.00 to 45.00; <a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a>; 124 participants; <a href="./references#CD013506-fig-0027" title="">Analysis 3.5</a>). However, data were too limited for us to be able to reach a conclusion. </p> </section> <section id="CD013506-sec-0088"> <h5 class="title">Symptom scores measuring breathlessness, cough and sputum production using validated scales </h5> <p>There was no report on this outcome.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013506-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013506-sec-0089"></div> <p>This systematic review evaluated RCTs that assessed the effects of magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease in adults. We included a total of 11 RCTs (10 double‐blind and one single‐blind) conducted in Iran, New Zealand, Nepal, Turkey, the UK, Tunisia and the USA between 2004 and 2018. We judged these studies to be at low or unclear risk of bias for most of the domains. We considered three studies to be at high risk for blinding and other biases. There were a total of 762 participants, whose mean ages ranged from 62 to 76 years. </p> <section id="CD013506-sec-0090"> <h3 class="title" id="CD013506-sec-0090">Summary of main results</h3> <section id="CD013506-sec-0091"> <h4 class="title">Intravenous magnesium sulfate versus placebo</h4> <p>We identified seven studies that assessed intravenous magnesium sulfate infusion versus placebo, with both arms receiving usual care. Low‐certainty evidence from three trials indicates that a smaller proportion of people required hospital admissions from the emergency room in the magnesium infusion group compared to the placebo group (170 participants, NNTB = 7). There was no clear difference in the need for non‐invasive ventilation. None of the participants in either group required endotracheal intubation or ICU admission or experienced serious adverse events. From a pooled analysis of two trials, length of hospital stay was shorter with magnesium infusion than placebo in 54 participants; we graded this as low‐certainty evidence. However, we could not be certain that the same benefit of reducing hospital admissions and the length of hospital stay would be observed in the larger population with COPD exacerbations.There was a lack of data on all‐cause mortality. Two studies reported no adverse events in the magnesium group; however, four participants in the placebo arm reported adverse events, with no clinically important difference between the groups. No clear difference was observed for lung function between magnesium infusion and placebo, as measured by change from baseline in FEV<sub>1</sub> at 60 minutes, post‐intervention FEV<sub>1</sub> and change from baseline PEFR at 45 minutes. In one trial, which reported change in PEFR as percentage predicted, magnesium infusion demonstrated a possible improvement compared to placebo. There was low‐certainty evidence indicating that magnesium infusion reduced dyspnoea score in two trials that used different tools (Borg score and DSS score). One other study assessed the Borg score, but the change from baseline score was not available for meta‐analysis, which reduced our confidence in this finding. Magnesium infusion was no better than placebo in improving oxygen saturation. </p> </section> <section id="CD013506-sec-0092"> <h4 class="title">Nebulised magnesium sulfate versus placebo</h4> <p>Three trials studied nebulised magnesium compared to placebo in addition to standard care for acute COPD exacerbations. Magnesium inhalation was no better than placebo in reducing hospitalisation. ICU admission was lower in people who received magnesium inhalation than those in the placebo arm; however, the certainty of evidence was very low. The proportion of people who needed ventilatory support (NIV or assisted ventilation) and length of hospital stay were not different between nebulised magnesium and placebo groups. There were no reported serious adverse events in either of the groups. There was one reported death in the placebo arm; however, we were not confident to reach a conclusion due to the small number of participants. Little to no difference was observed in lung function in terms of post‐intervention FEV<sub>1</sub> and change from baseline PEFR at 60 minutes. Post‐intervention PEFR at 60 minutes was observed to be higher with nebulised magnesium compared to placebo in one trial, but data were too limited for us to be able to reach a conclusion. Likewise, very low‐certainty evidence demonstrated a reduction in dyspnoea with magnesium inhalation in a small trial with 20 participants. There was no clear difference in oxygen saturation between these two arms. </p> </section> <section id="CD013506-sec-0093"> <h4 class="title">Magnesium sulfate versus ipratropium bromide</h4> <p>One trial assessed inhaled magnesium sulfate plus intravenous magnesium sulfate compared to inhaled ipratropium bromide plus intravenous normal saline. We could not determine a clear difference between these groups in terms of hospital admission, endotracheal intubation and length of hospital stay (very low‐certainty evidence). Similarly, all‐cause mortality was not different for these two arms. However, change in PEFR was observed to be greater for the ipratropium and placebo arm compared to the magnesium sulfate arm. Due to the small number of participants, few events and study limitations, we could not draw a robust conclusion. </p> </section> </section> <section id="CD013506-sec-0094"> <h3 class="title" id="CD013506-sec-0094">Overall completeness and applicability of evidence</h3> <p>We identified a total of 11 RCTs eligible for this review: seven trials that investigated intravenous magnesium sulfate infusion compared to placebo; three trials on nebulised magnesium sulfate versus placebo; and one trial that assessed combined intravenous and nebulised magnesium sulfate versus nebulised ipratropium bromide plus placebo. All of these trials determined the efficacy of magnesium in COPD exacerbations as an adjunctive measure to the usual standard care including oxygen, antibiotics, bronchodilators and systemic corticosteroids. </p> <p>The findings for magnesium infusion were based on analyses that involved one or two small studies with few participants, which is a limitation of the evidence. We could not determine any benefit of magnesium sulfate compared to ipratropium bromide, due to limited studies and relatively unreliable data. Based on a single trial, there was little to no difference between magnesium and ipratropium in hospital admission, length of hospital stay, all‐cause mortality or the need for endotracheal intubation. The trial did not report on ICU admission, non‐invasive ventilation, adverse events, serious adverse events, dyspnoea score or oxygen saturation. </p> <p>Most studies were conducted in single‐ or two‐centre settings with a small number of participants, which is the major limitation that impacts our ability to apply the evidence of this review to clinical practice in managing people with COPD exacerbations. The trials were based in middle‐ to high‐income countries, which may limit the applicability of the findings to low‐income countries. Current guidelines recommend the use of a single dose of magnesium sulfate infusion in acute exacerbation of bronchial asthma not responding to standard care. The trials in this review included adults over the age of 35 who were clinically diagnosed with COPD exacerbations. There were no specific criteria described for exclusion of people with overlap asthma features (asthma COPD overlap), except in the study by <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a> which excluded participants having asthma‐type COPD. Thus, we could not rule out the possibility that the findings in this review are partly contributed by participants who had asthma COPD overlap features. We had planned to do subgroup analyses by blood eosinophil count to find out which group of people with COPD exacerbations would benefit from magnesium sulfate, but could not do so due to limited data. Similarly, none of the included studies reported the disease severity of participants, so we could not investigate the effects of magnesium sulfate in particular groups of people with COPD exacerbations. </p> </section> <section id="CD013506-sec-0095"> <h3 class="title" id="CD013506-sec-0095">Quality of the evidence</h3> <p>Studies that contributed to the outcomes of this review were single‐ or two‐centre double‐blind RCTs with small number of participants, and one single‐blind trial. The majority of studies were at unclear risk of bias in several domains due to lack of information, with the exception of <a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a>, in which reporting was sufficiently clear for us to make low risk judgements for every domain. Comparisons for the outcomes were direct and most of the outcomes were based on one or two trials without any significant heterogeneity. Reasons for downgrading were mainly due to study limitations and imprecision of the pooled effect estimates (including wide or very wide confidence intervals, and small participant numbers). </p> <p>We rated the certainty of evidence for intravenous magnesium sulfate infusion to be low for hospital admission, length of hospital stay, symptomatic improvement and lung function (FEV<sub>1</sub>); and very low for non‐invasive ventilation and oxygen saturation. As for inhaled magnesium, the level of certainty was very low for all outcomes. Therefore, we have very little confidence in the effect estimates for magnesium inhalation compared to placebo. Similarly, the level of certainty was very low for the key outcomes (hospital admission, endotracheal intubation and length of hospital stay) for comparison between magnesium sulfate and ipratropium bromide. </p> <p>Pooled effects for nebulised magnesium were based on data from three trials, which we judged to be of poor quality with unclear risk for selection, detection and reporting biases. One trial was a single‐blinded study where investigators were unblinded, and another trial included only 20 participants (10 in each arm). The effects of nebulised magnesium sulfate on hospital admission, need for ventilatory support (NIV or assisted ventilation), length of hospital stay, lung function and oxygen saturation were of very low‐certainty evidence. No clear benefit could be demonstrated in improving these outcomes with the use of nebulised magnesium sulfate as an adjunctive therapy to usual standard care in COPD exacerbations compared to placebo. ICU admission was reportedly lower in participants who received magnesium inhalation compared to those in the placebo group. Likewise, dyspnoea measured by VAS score was observed to improve with nebulised magnesium compared to placebo in 20 participants. However, we are not confident of these findings, and data from larger multicentre trials are required to provide more robust evidence. We could not identify enough evidence to say that magnesium inhalation was not associated with important harms such as all‐cause mortality, adverse events or serious adverse events. Similarly, there is very limited evidence to support the efficacy of nebulised magnesium sulfate as an adjunctive therapy for COPD exacerbations. </p> <p>We planned to perform subgroup analyses if we found high levels of heterogeneity; however, this was not necessary as there was low heterogeneity. We could not investigate publication bias because of the small number of studies in analyses. Overall, we are not confident in the pooled effect estimates of this review, since the majority were calculated using data from one or two single/double centre trials that determined the effect of magnesium sulfate on a relatively small number of participants with COPD exacerbations. Additional information from further multicentre trials in a larger population is very likely to alter our confidence in these results and provide a better evidence for clinical practice. </p> </section> <section id="CD013506-sec-0096"> <h3 class="title" id="CD013506-sec-0096">Potential biases in the review process</h3> <p>This review was based on a published protocol (<a href="./references#CD013506-bbs2-0110" title="NiH , NaingC , AyeSZ .Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD013506. [DOI: 10.1002/14651858.CD013506]">Ni 2020</a>), and any deviations from the published protocol were noted in <a href="#CD013506-sec-0117">Differences between protocol and review</a>. Incomplete identification of studies for this review is unlikely as we performed a comprehensive search of databases, websites, clinical trial registries and reference lists. However, there are areas which may have introduced bias into the review. We identified one trial registered in the Iranian Registry of Clinical Trials (IRCT) that planned to start in 2016. We contacted the trial investigators for its current status but received no reply. We also contacted the authors of included trials for details of study characteristics and clarification on data. Only <a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a> replied and provided the necessary information about the trial. <a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a> assessed some outcomes relevant to this review, but only lung function data were available; dyspnoea score and oxygen saturation could not be included in the analyses. <a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> was a single‐blinded study, unregistered on a trial registry, with limited information on the conduct of the trial, which downgrades our confidence in its data. Moreover, two included trials were only available as abstracts with no full text publication (<a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a>; <a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a>), resulting in high risk of bias. In addition, assessment of publication bias through examination of funnel plots was not possible because only one or two trials were included in the analyses. </p> <p>Recently, the European Respiratory Society issued a statement on core outcomes for clinical trials assessing AECOPD (acute exacerbations of COPD) management, which included mortality (any cause or due to COPD exacerbations), treatment success, need for higher level of care (hospital or ICU admission), arterial blood gases, patient‐reported outcomes (breathlessness, quality of life, activities of daily living), disease progression, future exacerbations and hospital admissions, treatment safety (adverse events) and adherence (<a href="./references#CD013506-bbs2-0083" title="MathioudakisAG , AbrougF , AgustiA , AnanthS , BakkeP , BartziokasK , et al.DECODE-NET. ERS Statement: A core outcome set for clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations. European Respiratory Journal2022;59:2102006. [DOI: 10.1183/13993003.02006-2021] [PMID: 34649975]">Mathioudakis 2022</a>). The intended outcomes of this review are included in this recommended outcome set, except for length of hospital stay and lung function improvement. However, we were not able to synthesise evidence for all the planned outcomes since most of the COPD exacerbation trials assessed lung function as the primary outcome and clinically relevant outcomes were usually not included. Therefore, it is likely that this review is lacking in evidence for patient‐centred, clinically important outcomes. </p> </section> <section id="CD013506-sec-0097"> <h3 class="title" id="CD013506-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>There is limited evidence for the role of magnesium sulfate in acute COPD exacerbations, with very few published reviews to date. We could only identify three similar published systematic reviews focusing on the effects of magnesium in COPD exacerbations (<a href="./references#CD013506-bbs2-0032" title="AlzaidH , AldossariF , Bin NafisahS .Magnesium administration for COPD exacerbation: a systematic review and meta-analysis. Journal of Medicine, Law and Public Health2021;1(3):38-46. [DOI: 10.52609/jmlph.v1i3.22]">Alzaid 2021</a>; <a href="./references#CD013506-bbs2-0070" title="JahangirA , ZiaZ , NiaziMR , SahraS , JahangirA , SharifMA , et al.Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: a systematic review and meta-analysis. Advances in Respiratory Medicine 2022 Jan 31 [Epub ahead of print]. [DOI: 10.5603/ARM.a2022.0012] [PMID: 35099052]">Jahangir 2022</a>; <a href="./references#CD013506-bbs2-0099" title="ShivanthanMC , RajapakseS .Magnesium for acute exacerbation of chronic obstructive pulmonary disease: a systematic review of randomised trials. Annals of Thoracic Medicine2014;9(2):77-80.">Shivanthan 2014</a>). Intravenous magnesium reduced hospital admission in our analysis with a NNTB of seven. Two of the earlier published reviews failed to detect this (<a href="./references#CD013506-bbs2-0032" title="AlzaidH , AldossariF , Bin NafisahS .Magnesium administration for COPD exacerbation: a systematic review and meta-analysis. Journal of Medicine, Law and Public Health2021;1(3):38-46. [DOI: 10.52609/jmlph.v1i3.22]">Alzaid 2021</a>; <a href="./references#CD013506-bbs2-0099" title="ShivanthanMC , RajapakseS .Magnesium for acute exacerbation of chronic obstructive pulmonary disease: a systematic review of randomised trials. Annals of Thoracic Medicine2014;9(2):77-80.">Shivanthan 2014</a>), possibly due to their searches predating the publication of the latest trial included in our analysis (<a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a>, which had a relatively large number of participants. However, the recent review by <a href="./references#CD013506-bbs2-0070" title="JahangirA , ZiaZ , NiaziMR , SahraS , JahangirA , SharifMA , et al.Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: a systematic review and meta-analysis. Advances in Respiratory Medicine 2022 Jan 31 [Epub ahead of print]. [DOI: 10.5603/ARM.a2022.0012] [PMID: 35099052]">Jahangir 2022</a> identified a reduction in hospital admissions with intravenous magnesium, reporting the same summary statistics as our review. Shortening of hospital stay and improvement in dyspnoea score with magnesium infusion were not detected in these reviews. Variable severity of COPD exacerbations in the included trials could affect our findings on hospital admissions and length of hospital stay; however, the available baseline characteristics are comparable across the intervention arms. </p> <p>Low serum magnesium level is an important predictor of frequency of acute COPD exacerbations (<a href="./references#CD013506-bbs2-0037" title="AzizHS , BlamounAI , ShubairMK , IsmailMM , DeBariVA , KhanMA .Serum magnesium levels and acute exacerbation of chronic obstructive pulmonary disease: a retrospective study. Annals of Clinical and Laboratory Science2005;35(4):423-7. [PMID: 16254259]">Aziz 2005</a>; <a href="./references#CD013506-bbs2-0065" title="GumusA , HazirogluM , GunesY .Association of serum magnesium levels with frequency of acute exacerbations in chronic obstructive pulmonary disease: a prospective study. Pulmonary Medicine2014;2014:329476. [DOI: 10.1155/2014/329476] [PMID: 25485151]">Gumus 2014</a>; <a href="./references#CD013506-bbs2-0075" title="KshirsagarK , PatilVC .Chronic obstructive pulmonary disease: Is serum magnesium level risk factor for its acute exacerbation?Caspian Journal of Internal Medicine2021;12(2):223-7. [DOI: 10.22088/cjim.12.2.223]">Kshirsagar 2021</a>). Furthermore, low serum magnesium level at the time of admission was reported to be an independent predictor of readmission for AECOPD (<a href="./references#CD013506-bbs2-0038" title="BhattSP , KhandelwalP , NandaS , StoltzfusJC , FioravantiGT .Serum magnesium is an independent predictor of frequent readmissions due to acute exacerbation of chronic obstructive pulmonary disease. Respiratory Medicine2008;102(7):999-1003. [PMID: 18396393]">Bhatt 2008</a>). Since the participants in our analyses had normal serum magnesium levels, which were similar for both groups, we are quite confident that serum magnesium level at the time of presentation to the emergency room had no significant impact on our finding of hospital admission. </p> <p>Our review failed to yield a positive effect of magnesium infusion on lung function in terms of FEV<sub>1</sub> or oxygen saturation. This finding was shared by <a href="./references#CD013506-bbs2-0070" title="JahangirA , ZiaZ , NiaziMR , SahraS , JahangirA , SharifMA , et al.Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: a systematic review and meta-analysis. Advances in Respiratory Medicine 2022 Jan 31 [Epub ahead of print]. [DOI: 10.5603/ARM.a2022.0012] [PMID: 35099052]">Jahangir 2022</a>, which also showed no significant change in FEV<sub>1</sub> using a random‐effects model, though the fixed‐effect analysis demonstrated a significant effect. In our review, there was a possible improvement in PEFR, calculated as change from baseline percentage of predicted value. A similar finding was reported by <a href="./references#CD013506-bbs2-0099" title="ShivanthanMC , RajapakseS .Magnesium for acute exacerbation of chronic obstructive pulmonary disease: a systematic review of randomised trials. Annals of Thoracic Medicine2014;9(2):77-80.">Shivanthan 2014</a> as an increase in PEFR, with a mean percentage change of 24%. Due to considerable variability between FEV<sub>1</sub> and PEFR, especially when expressed as percentage of predicted value (<a href="./references#CD013506-bbs2-0081" title="LlewellinP , SawyerG , LewisS , ChengS , WeatherallM , FitzharrisP , et al.The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction. Respirology2002;7(4):333-7. [DOI: 10.1046/j.1440-1843.2002.00417.x] [PMID: 12421241]">Llewellin 2002</a>), FEV<sub>1</sub> is the preferred measure of airway obstruction in COPD exacerbations (<a href="./references#CD013506-bbs2-0053" title="EmermanCL , CydulkaRK .Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease. Annals of Emergency Medicine1996;27(2):159-63. [DOI: 10.1016/s0196-0644(96)70317-7] [PMID: 8629745]">Emerman 1996</a>). Thus, this finding is not strong enough for clinical use and requires further data for assessing the role of magnesium for lung function improvement. </p> <p>None of the previous reviews supported the efficacy of magnesium sulfate inhalation in COPD exacerbations compared to placebo, which is not altered by the results of our review. Similarly, evidence for nebulised magnesium versus ipratropium bromide is limited, with only one available trial. This consolidates the need for further well‐designed trials that extensively investigate the effects of magnesium sulfate, to yield better certainty evidence for its clinical use in COPD exacerbations. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013506-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013506-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD013506-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 1: Proportion of people with hospital admissions (from the emergency room)" data-id="CD013506-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 1: Proportion of people with hospital admissions (from the emergency room) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 2: Proportion of people with need for non‐invasive ventilation (NIV)" data-id="CD013506-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 2: Proportion of people with need for non‐invasive ventilation (NIV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 3: Length of hospital stay (days)" data-id="CD013506-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 3: Length of hospital stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 4: Proportion of people with adverse events" data-id="CD013506-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 4: Proportion of people with adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 5: Change in SpO 2 (%)" data-id="CD013506-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 5: Change in SpO <sub>2</sub> (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 6: FEV 1 change from baseline at 60 min (L)" data-id="CD013506-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 6: FEV <sub>1</sub> change from baseline at 60 min (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 7: FEV 1 at 45 min (mL)" data-id="CD013506-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 7: FEV <sub>1</sub> at 45 min (mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 8: Change in PEFR (L/min)" data-id="CD013506-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 8: Change in PEFR (L/min) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 9: Change in PEFR (% predicted)" data-id="CD013506-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 9: Change in PEFR (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 10: Change in dyspnoea score" data-id="CD013506-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Intravenous magnesium sulfate + standard care versus placebo + standard care, Outcome 10: Change in dyspnoea score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 1: Proportion of people with hospital admissions (from the emergency room)" data-id="CD013506-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 1: Proportion of people with hospital admissions (from the emergency room) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 2: Proportion of people who need ICU admission" data-id="CD013506-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 2: Proportion of people who need ICU admission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 3: Proportion of people who need ventilatory support (non‐invasive ventilation or assisted ventilation)" data-id="CD013506-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 3: Proportion of people who need ventilatory support (non‐invasive ventilation or assisted ventilation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 4: Length of hospital stay (days)" data-id="CD013506-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 4: Length of hospital stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 5: All‐cause mortality" data-id="CD013506-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 5: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 6: FEV 1 at 60 min (L)" data-id="CD013506-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 6: FEV <sub>1</sub> at 60 min (L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 7: PEFR change from baseline at 60 min (L/min)" data-id="CD013506-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 7: PEFR change from baseline at 60 min (L/min) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 8: PEFR at 60 min (L/min)" data-id="CD013506-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 8: PEFR at 60 min (L/min) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 9: Change in dyspnoea score" data-id="CD013506-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 9: Change in dyspnoea score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 10: Change in SaO 2 (%)" data-id="CD013506-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Nebulised magnesium sulfate + standard care versus placebo + standard care, Outcome 10: Change in SaO <sub>2</sub> (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 1: Proportion of people with hospital admissions (from the emergency room)" data-id="CD013506-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 1: Proportion of people with hospital admissions (from the emergency room) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 2: Proportion of people with the need for endotracheal intubation" data-id="CD013506-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 2: Proportion of people with the need for endotracheal intubation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 3: Length of hospital stay (days)" data-id="CD013506-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 3: Length of hospital stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 4: All cause mortality" data-id="CD013506-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 4: All cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013506-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/urn:x-wiley:14651858:media:CD013506:CD013506-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 5: Change in PEFR (L/min)" data-id="CD013506-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_t/tCD013506-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Magnesium sulfate versus standard care (ipratropium bromide), Outcome 5: Change in PEFR (L/min) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/media/CDSR/CD013506/image_n/nCD013506-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013506-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravenous magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intravenous magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute exacerbations of chronic obstructive pulmonary disease<br/><b>Setting:</b> emergency department<br/><b>Intervention:</b> intravenous magnesium sulfate + standard care<br/><b>Comparison:</b> placebo + standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravenous magnesium sulfate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people with hospital admissions (from the emergency room)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>593 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>396 per 1000<br/>(251 to 562) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.45<br/>(0.23 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people requiring non‐invasive ventilation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>314 per 1000<br/>(161 to 519) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/>(0.31 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no people who need endotracheal intubation in either magnesium or placebo groups. No trial assessed ICU admission. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people with serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no reported serious adverse events for magnesium and placebo groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay ranged from 5.47 to 7.33 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.7 days shorter<br/>(4.73 shorter to 0.66 shorter) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in oxygen saturation (SpO<sub>2</sub>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SpO<sub>2</sub> was 8.42% </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.32% higher<br/>(1.53 lower to 2.17 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in dyspnoea score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dyspnoea score ranged from 1.08 to 2.05</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 1.4 lower<br/>(1.83 lower to 0.96 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DSS score and Borg dyspnoea score were used. The lower the score, the lesser the severity of dyspnoea. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function: FEV<sub>1</sub> change from baseline at 60 min </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> at 60 min was 0.043 L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.0 L<br/>(0.04 lower to 0.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><br/>CI: confidence interval; DSS: dyspnoea severity score; FEV<sub>1</sub>: forced expiratory volume in 1 second; RCT: randomised controlled trial; OR: odds ratio; MD: mean difference; SpO<sub>2</sub>: peripheral oxygen saturation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations (risk of selection, performance, detection and reporting bias)<br/><sup>b</sup>Downgraded one level for serious imprecision (few events or wide confidence interval)<br/><sup>c</sup>Downgraded two levels for very serious imprecision (few events and CI includes both appreciable benefit and harm) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravenous magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013506-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nebulised magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Nebulised magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute exacerbations of chronic obstructive pulmonary disease<br/><b>Setting:</b> emergency department<br/><b>Intervention:</b> nebulised magnesium sulfate + standard care<br/><b>Comparison:</b> placebo + standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with nebulised magnesium sulfate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people with hospital admissions (from the emergency room)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>918 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>896 per 1000<br/>(702 to 969) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.77<br/>(0.21 to 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people requiring ICU admission</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/>(18 to 109) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.39<br/>(0.15 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people requiring ventilatory support (NIV or assisted ventilation)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(0 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.33<br/>(0.01 to 8.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of people with serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No trial assessed this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay was 10.2 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.8 lower<br/>(4.63 lower to 3.03 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in oxygen saturation (SaO<sub>2</sub>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in SaO<sub>2</sub> was 4% </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.1% lower<br/>(4.6 lower to 2.4 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in dyspnoea score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dyspnoea score was 9.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 14.37 lower<br/>(26 lower to 2.74 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS dyspnoea score was used. The higher the score, the greater the severity of dyspnoea.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function: FEV<sub>1</sub> at 60 min </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> at 60 min was 0.81 L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.05 L lower<br/>(0.17 lower to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in 1 second; ICU: intensive care unit ; RCT: randomised controlled trial; SaO<sub>2</sub>: arterial oxygen saturation; OR: odds ratio; MD: mean difference; VAS: visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations (risk of selection and reporting bias)<br/><sup>b</sup>Downgraded two levels for study limitations (risk of selection, reporting bias and very small participant numbers)<br/><sup>c</sup>Downgraded two levels for very serious imprecision (few events and CI includes both appreciable benefit and harm)<br/><sup>d</sup>Downgraded one level for serious imprecision (few events or CI includes non‐appreciable benefit and potential harm)<br/><sup>e</sup>Downgraded two levels for study limitations (single blinded study with high risk of performance bias) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nebulised magnesium sulfate + standard care compared to placebo + standard care for acute exacerbations of chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013506-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Magnesium sulfate compared to standard care (ipratropium bromide) for acute exacerbations of chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Magnesium sulfate compared to (standard care) ipratropium bromide for acute exacerbations of chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute exacerbations of chronic obstructive pulmonary disease<br/><b>Setting:</b> emergency department<br/><b>Intervention:</b> magnesium sulfate<br/><b>Comparison:</b> ipratropium bromide </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ipratropium bromide</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with magnesium sulfate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people with hospital admissions (from the emergency room)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>323 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000<br/>(271 to 616) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.62<br/>(0.78 to 3.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of people requiring endotracheal intubation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000<br/>(72 to 375) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.69<br/>(0.61 to 4.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU admission or non‐invasive ventilation not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of people with serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay was 6.6 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.1 higher<br/>(0.22 lower to 2.42 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in oxygen saturation (SaO<sub>2</sub>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in dyspnoea score</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lung function: FEV<sub>1</sub> at 60 min </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; FEV<sub>1</sub>: forced expiratory volume in 1 second; ICU: intensive care unit ; RCT: randomised controlled trial; SaO<sub>2</sub>: arterial oxygen saturation; OR: odds ratio; MD: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (few events and CI includes both appreciable benefit and harm)<br/><sup>b</sup>Downgraded one level for study limitations (risk of detection and other bias) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Magnesium sulfate compared to standard care (ipratropium bromide) for acute exacerbations of chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013506-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study centres</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study location</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number randomised</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Concomitant treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Hospitalisations<br/>in the last 12<br/>months, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ICU admission in the last 12<br/>months</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serum magnesium level:</b> mean (SD) </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0001" title="BajracharyaM , AcharyaRP , NeupaneRP , SthapitR , TamrakarAR .Nebulized magnesium sulphate versus saline as an adjuvant in acute exacerbation of chronic obstructive pulmonary disease in a tertiary centre of Nepal: a randomised control study. Journal of Institute of Medicine Nepal2021;43(1):5-10. [DOI: 10.3126/jiom.v43i1.37461]">Bajracharya 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nepal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised MgSO<sub>4</sub> + Nebulised salbutamol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + nebulised salbutamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen, ipratropium, hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0002" title="ComertS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in infective exacerbations of chronic obstructive pulmonary disease. Tuberkuloz ve Toraks2016;64(1):17-26. SunmezS , KiyanE , OkumusG , ArsevenO , EceT , IsseverH .Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal2006;28(Suppl 50):1275. ">Comert 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised MgSO<sub>4</sub> + standard care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen, steroids, antibiotics and ipratropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO<sub>4</sub>: 3 (30) </p> <p>Placebo: 4 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4: 0</p> <p>Placebo: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0003" title="ACTRN12608000167369.A study to investigate the effects of nebulised magnesium in severe exacerbations of chronic obstructive pulmonary disease (COPD). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82699 (first received 27 March 2008). EdwardsL , ShirtcliffeP , WadsworthK , HealyB , JefferiesS , WeatherallM , et al.Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax2013;68(4):338-43. [PMID: 23299960]">Edwards 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised MgSO<sub>4</sub> + Nebulised salbutamol </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + nebulised salbutamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO<sub>4</sub>: 1 </p> <p>Placebo: 1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mmol/L</p> <p>MgSO<sub>4</sub>: 0.81 (0.08) </p> <p>Placebo: 0.78 (0.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0004" title="HoggJS , MulrenanSA , EverettC , MoriceAH .A single centre double blind placebo controlled pilot study in the use of intravenous magnesium sulphate for the treatment of acute exacerbation of chronic obstructive airways disease (COPD). European Respiratory Journal2004;24:343s. ">Hogg 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0005" title="IRCT20150315021480N8.The effect of intravenous magnesium sulfate as a complementary therapy to COPD [Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department]. en.irct.ir/trial/18822 (first received 9 May 2018). JahanianF , KhatirIG , AhidashtiHA , AmirifardS .The effect of intravenous magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in the emergency department: a double-blind randomised clinical trial. Ethiopian Journal of Health Sciences2021;31(2):267-74. [PMID: 34158778]">Jahanian 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen, inhaled salbutamol and ipratropium, intravenous hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0006" title="IRCT2014111519962N1.The effect of IV magnesium sulfate on dyspnoea improving of patients with chronic obstructive pulmonary disease. en.irct.ir/trial/17716 (first received 4 February 2015). Vafadar MoradiE , PishbinE , HabibzadehSR , Talebi DolueeM , SoltanifarA .The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled clinical trial. Academic Emergency Medicine2021;28(3):359-62. ">Moradi 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen, nebulised salbutamol, nebulised<br/>ipratropium, IV hydrocortisone, IV antibiotics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0007" title="ACTRN12613000837729.Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease [Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364675 (first received 25 July 2013). MukerjiS , ShahpuriB , Clayton-SmithB , SmithN , ArmstrongP , HardyM , et al.Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. New Zealand Medical Journal2015;128(1425):34-42. [PMID: 26905985]">Mukerji 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised salbutamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mmol/L</p> <p>MgSO<sub>4</sub>: 0.79 (0.1) </p> <p>Placebo: 0.78 (0.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0008" title="NCT01136421.Magnesium sulfate versus ipratropium bromide in acute exacerbation of chronic obstructive pulmonary disease. clinicaltrials.gov/ct2/show/NCT01136421 (first received 3 June 2010). NouiraS , BouidaW , GrissaMH , BeltaiefK , TrimechMN , BoubakerH , et al.Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomised trial. American Journal of Therapeutics2014;21(3):152-8. [PMID: 22407196]">Nouira 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tunisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised MgSO<sub>4</sub> + IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised ipratropium + IV normal saline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV methyl prednisolone, antibiotics,<br/>and nebulised terbutaline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO<sub>4</sub>: 3.6 (2.4) </p> <p>Ipratropium: 3.1 (1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0009" title="PishbinE , MoradiEV .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD: a randomised controlled trial. Critical Care2018;22(Suppl 1):P228. PishbinE .Intravenous magnesium sulfate in the treatment of acute exacerbations of COPD. Journal of Emergency Medicine2017;53(3):442-3. ">Pishbin 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion + standard care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0010" title="SkorodinMS , TenholderMF , YetterB , OwenKA , WallerRF , KhandelwahlS , et al.Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Archives of Internal Medicine1995;155(5):496-500. [PMID: 7864705]">Skorodin 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised albuterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mmol/L</p> <p>MgSO<sub>4</sub>: 0.94 (0.16) </p> <p>Placebo: 0.98 (0.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013506-bbs2-0011" title="SolookiM , MiriM , MokhtariM , ValaiM , SistanizadM , KouchekM .Magnesium sulfate in exacerbations of COPD in patients admitted to internal medicine ward. Iranian Journal of Pharmaceutical Research2014;13(4):1235-9. [PMID: 25587312]">Solooki 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV MgSO<sub>4</sub> infusion + standard treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bronchodilators, oxygen, corticosteroid and antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO<sub>4</sub>: 9 (60)<br/>Placebo: 10 (67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mEq/L</p> <p>MgSO<sub>4</sub>: 2.11 (0.28) </p> <p>Placebo: 2.05 (0.40)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: MgSO<sub>4</sub>: magnesium sulfate; NR: not reported </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/full#CD013506-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013506-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous magnesium sulfate + standard care versus placebo + standard care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion of people with hospital admissions (from the emergency room) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.23, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Proportion of people with need for non‐invasive ventilation (NIV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.31, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐4.73, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Proportion of people with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Change in SpO <sub>2</sub> (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 FEV <sub>1</sub> change from baseline at 60 min (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 FEV <sub>1</sub> at 45 min (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Change in PEFR (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.12 [‐6.20, 24.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Change in PEFR (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Change in dyspnoea score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐1.83, ‐0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravenous magnesium sulfate + standard care versus placebo + standard care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013506-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Nebulised magnesium sulfate + standard care versus placebo + standard care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Proportion of people with hospital admissions (from the emergency room) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion of people who need ICU admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.15, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Proportion of people who need ventilatory support (non‐invasive ventilation or assisted ventilation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 FEV <sub>1</sub> at 60 min (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 PEFR change from baseline at 60 min (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 PEFR at 60 min (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Change in dyspnoea score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Change in SaO <sub>2</sub> (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Nebulised magnesium sulfate + standard care versus placebo + standard care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013506-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Magnesium sulfate versus standard care (ipratropium bromide)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Proportion of people with hospital admissions (from the emergency room) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Proportion of people with the need for endotracheal intubation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Change in PEFR (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Magnesium sulfate versus standard care (ipratropium bromide)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013506.pub2/references#CD013506-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013506.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013506-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013506-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013506-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013506-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013506-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD013506-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013506-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013506-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013506\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013506\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013506\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013506\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013506\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013506.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013506.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013506.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013506.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013506.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719101764"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013506.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719101767"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013506.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de08a79c61be4',t:'MTc0MDcxOTEwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 